| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Waters Corporation$374.41
-2.48 (-0.66%)
D 27Pipeline Score Diagnostics · Commercial
Market Cap
33.62 B
EPS
7.88
P/E Ratio
43.58 $
Value Trade
346.44 M
SEC Financials
Q2 2026Dilution Risk
Revenue
1.27 B
R&D Expenses
96.00 M
Operating CF
-3.00 M
Total Assets
24.53 B
Total Liabilities
9.24 B
Equity
15.29 B
D/E Ratio
12,345
4.31 %
Week
1.72 %
1 Month
4.69 %
3 Month
-9.55 %
6 Month
9.67 %
5 Year
8,954.41 %
All Time
Cash Data
Cash Position
462.00 M
Monthly Burn
1.00 M
Runway
460.5 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
2.03 M
52 Week Range
275.05 - 414.15
% held by Insiders
0.15 %
% held by Institutions
99.78 %
Enterprise Value
38.72 B
Total Shares
98.16 M
Short %
4.61 %
Float Shares
97.86 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D27
Pipeline Score $31M
Pipeline ValueValuation Signal
1
Drugs Scored0.0x
rNPV / MCap Top 29%
Mid Cap (rank 644 of 905)
Percentile RankWaters Corporation faces pipeline headwinds (27/100), with $37M risk-adjusted pipeline value, led by CYTALUX preoperatively in Esophageal Cancer (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CYTALUX preoperatively Small molecule | Esophageal Cancer | Phase 2 | NCT07039526 | 10% | $37M | RECRUITING | 50 | - | - | Dec 1, 2027 | - | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in WAT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
WAT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
WAT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
WAT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
WAT Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
WAT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
WATSNT Biotech Announces a Partnership with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
SNT Biotech has partnered with Waters Corporation to enhance access to at-home cervical cancer screenings through the FDA-cleared Onclarity™ HPV Self-Collection Kit. This initiative aims to address the significant barriers to screening faced by underserved populations, with a focus on improving completion rates and early detection of cervical cancer. The partnership combines education and infrastructure to facilitate better health outcomes for women.
Read more →WATColor Partners with Waters Corporation to Bring the Most Comprehensive FDA-Cleared At-Home HPV Cervical Cancer Screening Tool Available in the U.S. Today to Patients
Color Health has launched the FDA-cleared Onclarity™ HPV Self-Collection Kit, enhancing at-home cervical cancer screening in the U.S. This innovative kit allows for comprehensive screening of high-risk HPV types and aims to improve accessibility for patients. The initiative is part of Color's broader cancer care program, which has shown a significant increase in screening adherence and faster diagnosis times.
Read more →WATIMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
IMU Biosciences has partnered with Waters Corporation to enhance its AI-driven immune mapping platform. This collaboration aims to analyze over 100 million data points from a single blood sample, improving early diagnosis and precision medicine. The partnership will leverage Waters' advanced technologies to expand IMU's immune dataset and establish new standards in immune profiling.
Read more →WATHighRes® and Waters Collaborate to Advance Drug Discovery through Robotic Automation
Waters Corporation is collaborating with HighRes® to enhance drug discovery processes through robotic automation. This partnership aims to streamline workflows and improve efficiency in pharmaceutical research. The collaboration highlights the ongoing trend of integrating advanced technologies in drug development.
Read more →WATWaters Launches Coin Cell Differential Scanning Calorimeter (DSC) to Advance Battery Safety with Integrated Thermal, Evolved Gas, and Electrochemical Analysis
Waters Corporation has launched the Coin Cell Differential Scanning Calorimeter (DSC), designed to enhance battery safety testing. This innovative device allows for simultaneous analysis of thermal behavior, evolved gas, and electrochemical performance, significantly reducing sample preparation time. With a temperature range from -80 °C to 600 °C, it streamlines workflows and provides critical insights into battery safety and performance.
Read more →WATWaters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis 55th International Symposium on High Performance Liquid Phase Separations and Related Techniques—Waters Corporation (NYSE: WAT) today announced the...
Waters Corporation has announced the launch of its BioResolve Peptide and GTxResolve Lipid Columns, which are designed to significantly enhance the separation of impurities in GLP-1 peptides and lipid nanoparticles. This new technology promises up to three times faster characterization of GLP-1 and twice the speed for lipid component analysis, potentially reducing costs and improving regulatory compliance. The columns feature specialized surface chemistries and particle designs to optimize separation efficiency in both HPLC and U(H)PLC systems. Beginning June 9, 2026, these innovative solutions aim to address critical challenges faced in biopharmaceutical development.
Read more →WATWaters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics Waters Corporation (NYSE: WAT) today announced that the BD BACTEC FXI Culture System has received U.S. Food and Drug Administration (FDA) 510(k)...
Waters Corporation has announced that the BD BACTEC FXI Culture System has received FDA 510(k) clearance, allowing for its commercialization in the U.S. This automated blood culture system aims to enhance the speed and accuracy of diagnosing bloodstream infections. Clinical data indicates that it can reduce the mean time to detection by approximately three hours compared to its predecessor, which is critical for patient outcomes. The system features advanced automation and an innovative measurement capability designed to improve overall diagnostic reliability in high-throughput laboratories.
Read more →WATWaters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics ResearchAPAC - EnglishUSA - EnglishUSA - English
Waters Corporation has launched the Xevo MRT P10 Mass Spectrometer, a high-resolution QToF system designed for multiomics research. This new mass spectrometer offers significantly enhanced sensitivity and speed, enabling researchers to detect low-abundance compounds more effectively. The system aims to accelerate biomarker discovery and improve therapeutic target identification in biomedical studies.
Read more →WATWaters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial OmicsAPAC - EnglishUSA - EnglishUSA - EnglishAPAC - Traditional Chinese
Waters Corporation has launched the Cyclic IMS P20 Mass Spectrometer, a cutting-edge platform designed for structural and spatial omics. This new instrument enhances sensitivity and resolution, allowing researchers to detect disease signals more effectively. The Cyclic IMS P20 combines multiple advanced techniques to provide comprehensive molecular insights, supporting accelerated discovery in biomedical research. It will be showcased at the ASMS 2026 conference and is set for global availability in September 2026.
Read more →WATWaters Corporation to Present at the Jefferies Global Healthcare Conference Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at...
Waters Corporation (NYSE: WAT) announced that CEO Udit Batra will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3rd, 2026. This event signifies an opportunity for Waters to discuss its innovations and commitment to life sciences. A live webcast of the presentation will be available for investors, and a replay will be accessible for 90 days. Waters continues to position itself as a leader in analytical technologies and services.
Read more →WATCaspar Tudor, Head of Investor Relations - (508) 482-3448 Waters Corporation (NYSE: WAT) Reports First Quarter 2026 Financial Results First Quarter 2026 Highlights Total reported revenue of
Waters Corporation (NYSE: WAT) announced its financial results for the first quarter of 2026, highlighting a total revenue of $1.267 billion, boosted by the acquisition of Becton, Dickinson and Company's Biosciences and Diagnostic Solutions businesses. The company experienced a 13% increase in organic revenue, with adjusted EPS rising by 20%. Despite these positive trends, Waters reported a diluted loss per share of $0.87 due to acquisition-related costs. The company has raised its full-year 2026 revenue guidance, indicating strong momentum in its operational performance.
Read more →WATWaters Corporation (NYSE: WAT) Reports First Quarter 2026 Financial Results
Waters Corporation reported strong financial results for Q1 2026, with total revenue of $1.267 billion, exceeding guidance. Organic revenue grew by 13%, and adjusted EPS rose by 20% year-over-year. The company has raised its full-year growth guidance due to strong performance in its Biosciences and Diagnostic Solutions segments following the recent acquisition. However, GAAP EPS showed a loss due to acquisition-related costs.
Read more →WATWaters Corporation Schedules First Quarter 2026 Earnings Conference Call
Waters Corporation has announced its Q1 2026 earnings conference call scheduled for May 5, 2026. The call will be accessible via a live webcast on the company's Investor Relations website. A replay will be available until June 2, 2026. This event reflects the company's commitment to keeping investors informed.
Read more →WATWaters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large MoleculesAPAC - EnglishUSA - EnglishUSA - EnglishAPAC - Traditional Chinese
Waters Corporation has launched the omniDAWN Multi-Angle Light Scattering (MALS) Photometer, the first extended-range MALS detector designed for UHPLC and UPLC workflows. This innovative device enhances the characterization of larger analytes, providing absolute molar mass and size measurements. The omniDAWN Photometer is expected to improve throughput and resolution in laboratories, supporting advanced therapeutic development.
Read more →WATWaters Announces CE Mark for Next-Generation Fully Automated BD BACTEC FXI Culture System for Bloodstream Infection Diagnosis Waters Corporation (NYSE: WAT) today announced that the BD BACTEC™ FXI Culture System has received CE marking under the European Union's In Vitro...
Waters Corporation has announced that its BD BACTEC FXI Culture System has received CE marking under the EU's In Vitro Diagnostic Regulation, allowing for commercialization in Europe. This next-generation system is designed to enhance bloodstream infection diagnostics by reducing detection time and improving accuracy through automated features. With an innovative gravimetric measurement capability, the system addresses diagnostic variability and supports modern laboratory workflows. It is set to be showcased at ESCMID Global 2026 in Munich, with plans for further regulatory approvals in additional markets.
Read more →WATWaters Announces FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay Waters Corporation (NYSE: WAT) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Onclarity HPV Self-Collection Kit and ...
Waters Corporation announced FDA clearance for the Onclarity HPV Self-Collection Kit and the BD Onclarity HPV Assay, facilitating at-home cervical cancer screening. This move aims to enhance accessibility to screening and improve early detection rates of cervical cancer. The kit, which is associated with high-risk HPV detection, has been endorsed by medical professionals as a significant advancement for patient care. The initiative is backed by research collaboration with the NIH, signaling a commitment to public health improvement.
Read more →WATWaters Prices Offering of Senior Notes Waters Corporation (NYSE: WAT) (the Company or Waters ) today announced that it has priced an offering (the Offering ) of $3.5 billion aggregate...
Waters Corporation has priced an offering of $3.5 billion senior notes through its subsidiary, Augusta SpinCo Corporation. The offering is expected to close around March 23, 2026, depending on customary conditions. The funds will be used to repay existing indebtedness incurred earlier this year. Several major financial institutions are participating as underwriters for the offering.
Read more →WATINDEX TO CONDENSED COMBINED FINANCIAL STATEMENTS Item Page Condensed Combined Statements of Income for the three months ended
The financial statements for Waters Corporation reveal a decrease in revenue and net income for the three months ending December 31, 2025, compared to the same period in 2024. Total net sales decreased from 834 million in 2024 to 766 million in 2025, with product sales declining as well. Meanwhile, the company incurred an increase in research and development expenses, which may impact future financial performance. The balance sheets indicate a reduction in total assets compared to the previous reporting period.
Read more →WATWaters Flagship ARES‑G3 Rheometer Sets New Benchmark for Data Quality at Breakthrough SpeedUSA - EnglishUSA - EnglishAPAC - English
Waters Corporation has launched the ARES-G3 Rheometer, a next-generation instrument that captures data at unprecedented speeds of up to 25,000 data points per second. This new rheometer reduces testing times by up to 80% and enhances data quality, addressing critical challenges in materials research. It integrates advanced features like Fast Frequency Chirps and improved software, facilitating better insights into complex material behaviors.
Read more →WATWaters Corporation to Present at the TD Cowen Health Care Conference
Waters Corporation will have its CEO, Udit Batra, participate in a fireside chat at the TD Cowen Health Care Conference on March 2, 2026. The event will be accessible via a live webcast, which will also be available for replay for 90 days. This participation emphasizes Waters' commitment to engaging with the healthcare community.
Read more →WATWaters Introduces Next-Generation Microflow LC Columns with MaxPeak Premier Technology, Delivering Higher Sensitivity with Lower Sample and Solvent Usage
Waters Corporation has launched new 1 mm I.D. liquid chromatography columns featuring MaxPeak Premier Technology. These columns enhance sensitivity while minimizing solvent and sample usage, making them ideal for bioanalysis and pharmaceutical development. The technology aims to improve recovery for complex molecules, addressing challenges in high-throughput labs. The columns will be available globally starting February 17, 2026.
Read more →WATWaters Completes Combination with BD's Biosciences & Diagnostic Solutions BusinessesAPAC - EnglishUSA - EnglishUSA - EnglishAPAC - Traditional Chinese
Waters Corporation has successfully completed its combination with Becton, Dickinson and Company's Biosciences & Diagnostic Solutions businesses. This merger positions Waters as a leader in life sciences and diagnostics, enhancing its capabilities with advanced technologies. The company also appointed Dr. Claire Fraser to its Board, bringing significant scientific expertise to guide future growth.
Read more →WATWaters Completes Combination with BD's Biosciences & Diagnostic Solutions BusinessesUSA - EnglishUSA - EnglishAPAC - English
Waters Corporation has successfully completed its combination with Becton, Dickinson and Company's Biosciences & Diagnostic Solutions businesses. This merger aims to create a leading entity in life sciences and diagnostics, enhancing their capabilities in high-volume testing and specialty diagnostics. Dr. Claire Fraser has been appointed to the board, bringing extensive expertise in genomics and molecular diagnostics.
Read more →WATWaters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2025 Financial Results
Waters Corporation reported strong financial results for Q4 and full-year 2025, with sales growth of 7% year-over-year. Non-GAAP EPS increased by 10% in Q4 2025, although GAAP EPS saw a slight decline. The company anticipates continued momentum into 2026, bolstered by the acquisition of BD Biosciences and ongoing innovation. Guidance for 2026 suggests robust revenue growth, with expectations for combined company sales growth.
Read more →WATCaspar Tudor, Head of Investor Relations - (508) 482-3448 Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2025 Financial Results Highlights Fourth Quarter 2025 Sales of
Waters Corporation reported its financial results for the fourth quarter and full year 2025, highlighting a 7% increase in sales compared to the previous year. Non-GAAP diluted EPS for Q4 2025 was $4.53, up from $4.10 year-over-year. The company's CEO emphasized the continued growth momentum into 2026, supported by the integration of BD Biosciences and operational improvements. Full-year 2026 revenue expectations indicate further growth potential, with estimated sales contributions from recent acquisitions.
Read more →WATWaters Shareholders Approve Combination with BD’s Biosciences & Diagnostic Solutions Business
Waters Corporation's shareholders have approved the merger with Becton, Dickinson and Company's Biosciences & Diagnostic Solutions business. The overwhelming approval, with approximately 99% in favor, paves the way for the transaction to close on February 9, 2026. Waters' CEO expressed optimism about future growth and innovation following the merger.
Read more →WATWaters Shareholders Approve Combination with BD's Biosciences & Diagnostic Solutions BusinessUSA - EnglishUSA - English
Waters Corporation shareholders have approved the issuance of shares to Becton, Dickinson and Company shareholders as part of the merger of BD's Biosciences & Diagnostic Solutions business with Waters. The transaction is anticipated to close on February 9, 2026, following the completion of customary closing conditions. Waters aims to enhance its position in life sciences and diagnostics through this combination.
Read more →WATWaters Corporation Schedules Fourth Quarter 2025 Earnings Conference Call
Waters Corporation has announced its Q4 2025 earnings conference call scheduled for February 12, 2026, at 8:00 a.m. Eastern Time. The call will be accessible via a live webcast on the company's Investor Relations website, with a replay available until March 12, 2026. This event highlights the company's ongoing commitment to transparency with investors.
Read more →WATForward-Looking Statements & Non-GAAP Financial Measures Forward-Looking Statements: This presentation includes "forward-looking statements" as that term is defined in Section 27A of the Securities Act of 1933, as amende
Waters Corporation provided a presentation at the J.P. Morgan 44th Annual Healthcare Conference detailing forward-looking statements and non-GAAP financial measures. The company discussed a proposed transaction involving itself, Becton, Dickinson and Company, and Augusta SpinCo Corporation. However, the presentation highlighted various risks and uncertainties that could affect the successful completion of this transaction, including potential regulatory hurdles and unforeseen costs. These factors could significantly impact the anticipated benefits of the merger and the operational performance of the combined entities.
Read more →WATWaters Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026
Waters Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Udit Batra is scheduled to speak at 2:15 PM PT. A live webcast will be available, along with a replay for 90 days. The company emphasizes its role in analytical instruments and technologies.
Read more →WATWaters Corporation to Present at the Jefferies Global Healthcare Conference in London
Waters Corporation will have its CEO, Udit Batra, participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 18, 2025. The event will be available via live webcast and will be accessible for replay for 90 days. This participation underscores Waters' commitment to engaging with the healthcare community.
Read more →WATWaters Boosts Lab Productivity and Sample Throughput with Launch of its Charged Aerosol Detector Designed for Empower SoftwareUSA - EnglishKorea - 한국어Japan - JapaneseUSA - EnglishAPAC - English
Waters Corporation has launched its Charged Aerosol Detector (CAD), designed for use with Empower Software, enhancing lab productivity and sample throughput. The CAD provides sensitive measurements for a variety of analytes without the need for pre-treatment. It addresses common issues faced by users of multi-vendor systems, ensuring a more reliable experience. The CAD is available for pre-order, with shipments expected by April 2026.
Read more →WATWaters Corporation (NYSE: WAT) Reports Third Quarter 2025 Financial Results
Waters Corporation reported strong financial results for Q3 2025, with sales reaching $800 million, an 8% increase from the previous year. Non-GAAP EPS rose by 16% to $3.40, despite a decline in GAAP EPS. The company is optimistic about future growth, particularly in its pharma segment and ongoing integration with BD's Biosciences & Diagnostic Solutions.
Read more →WATCaspar Tudor, Head of Investor Relations - (508) 482-3448 Waters Corporation (NYSE: WAT) Reports Third Quarter 2025 Financial Results Highlights Sales of $800 million exceeded guidance; gre
Waters Corporation reported strong third quarter results for 2025, with sales reaching $800 million, an 8% increase from the previous year. Non-GAAP diluted earnings per share also showed significant improvement, growing 16% compared to the same period in 2024. The company attributed its success to a robust product portfolio and strong performance in the pharma sector. Additionally, Waters raised its full-year revenue and earnings guidance, reflecting positive expectations for the remainder of the year.
Read more →WATWaters Launches Charge Detection Mass Spectrometry Technology to Accelerate the Development of Next-Generation Biotherapeutics Headlines: Xevo™ CDMS facilitates direct, accurate mass detection for the largest, most heterogeneous biomolecules.1 Enables accurate analysis of...
Waters Corporation has unveiled the Xevo Charge Detection Mass Spectrometer (CDMS), a new technology designed to enhance mass measurement of large biomolecules essential for biotherapeutics. This system addresses challenges in analyzing heterogeneous drug modalities with improved resolution and sensitivity. It allows for the direct analysis of molecules up to 150 MDa, thereby accelerating the development of genetic medicines and other advanced therapies. The innovative technology promises quicker results and lower sample volume requirements, which is expected to improve safety and efficacy in advanced therapy processes.
Read more →WATWaters Corporation Schedules Third Quarter 2025 Earnings Conference Call Waters Corporation (NYSE:WAT) will hold its Q3 2025 financial results conference call on Tuesday, November 4th, 2025 at 8:00 a.m. Eastern Time. A...
Waters Corporation has announced that it will hold its Q3 2025 earnings conference call on November 4th, 2025, at 8:00 a.m. Eastern Time. The call will be accessible via a live webcast on the company's Investor Relations website, with a replay available until December 2nd, 2025. Known for over 65 years in analytical instruments and technology, Waters serves critical sectors such as life sciences and environmental sciences.
Read more →WATWaters Corporation to Present at the Wells Fargo Healthcare Conference Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at...
Waters Corporation, led by CEO Udit Batra, will participate in a fireside chat at the upcoming Wells Fargo Healthcare Conference on September 4th, 2025. The event is expected to provide insights into the company's strategies and innovations in analytical technologies. Investors can tune in via a live webcast, which will also be available for replay for 90 days. This presentation highlights Waters' ongoing engagement in the healthcare sector and its commitment to transparency with stakeholders.
Read more →WATCaspar Tudor, Head of Investor Relations (508) 482-3448 Waters Corporation (NYSE: WAT) Reports Second Quarter 2025 Financial Results Highlights Sales of $771 million exceeded guidance range
Waters Corporation (NYSE: WAT) reported its financial results for Q2 2025, revealing sales of $771 million, a 9% increase from the previous year. The company's diluted EPS rose to $2.47, and non-GAAP EPS grew by 12% to $2.95. Effective execution of commercial growth initiatives and the adoption of new products contributed to this performance. Additionally, the company has raised its sales and earnings guidance for the full year 2025, reflecting positive market trends and successful strategies.
Read more →WATWaters Corporation (NYSE: WAT) Reports Second Quarter 2025 Financial Results Highlights Sales of $771 million exceeded guidance range; grew 9% as reported and 8% in constant currency GAAP EPS of $2.47 and non-GAAP EPS of...
Waters Corporation reported a strong financial performance for the second quarter of 2025, with sales reaching $771 million, marking a 9% increase compared to the previous year. The company also reported a GAAP EPS of $2.47 and a non-GAAP EPS of $2.95, reflecting robust growth driven by instrument replacement trends among large pharmaceutical and CDMO customers. As a result, Waters has raised its full-year sales and earnings guidance, indicating confidence in its continued growth and operational performance.
Read more →WATWaters and BD s Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing Strong strategic fit that increases presence in multiple hi
Waters Corporation and BD have announced an agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters, forming a leader in life sciences and diagnostics. Valued at approximately $17.5 billion, the merger is designed to enhance shareholder value and expand market access. The combined entity will operate under the Waters name and retain its NYSE listing as WAT. This strategic move positions both companies to leverage their complementary strengths and pursue growth in high-demand markets.
Read more →WATWaters Corporation Schedules Second Quarter 2025 Earnings Conference Call Waters Corporation (NYSE:WAT) will hold its Q2 2025 financial results conference call on Monday, August 4th, 2025 at 8:00 a.m. Eastern Time. A live...
Waters Corporation has announced a scheduled earnings conference call for its second quarter of 2025, set to take place on August 4, 2025, at 8:00 a.m. Eastern Time. Investors will have the opportunity to engage with the presentation through a live webcast, which will also be available for replay until at least September 2, 2025. The announcement reflects the company's commitment to transparency and investor relations.
Read more →WATWaters mejora el software del sistema Alliance iS HPLC - Waters mejora el software del sistema Alliance iS HPLC, estableciendo un nuevo estándar para la trazabilidad integral y la integridad de los datos...
Waters Corporation has announced the release of version 2.0 of its Alliance iS HPLC software, significantly enhancing data traceability and security for the pharmaceutical industry. This new version integrates user access control from the Empower software, establishing a new standard for data integrity. The improvements also aim to reduce human errors in quality control laboratories by up to 40%. Additionally, the product line has been recognized for its sustainable manufacturing practices, highlighting Waters' commitment to environmental responsibility.
Read more →WATWaters verbessert Alliance iS HPLC-System-Software und setzt damit einen neuen Standard für End-to-End-Rückverfolgbarkeit und Datenintegrität 54. Internationales Symposium über Hochleistungsflüssigkeitschromatographie und verwandte Techniken – Waters Corporation (NYSE: WAT) gab heute die...
Waters Corporation announced the release of Version 2.0 of its Alliance iS HPLC System Software at the 54th International Symposium on High-Performance Liquid Chromatography. The upgrade focuses on providing comprehensive end-to-end traceability and improved data integrity for the pharmaceutical industry. Features include enhanced user access control for optimal compliance and a reduction of human errors by 40%. The software will be available starting August 2025, and it has received accolades for sustainable manufacturing practices.
Read more →WATWaters Enhances Alliance iS HPLC System Software, Setting a New Standard for End-to-End Traceability and Data Integrity 54th International Symposium on High-Performance Liquid Phase Separations and Related Techniques - Waters Corporation (NYSE: WAT) today announced the ...
Waters Corporation has announced the release of the Alliance iS HPLC System Software version 2.0, enhancing traceability and data security for the pharmaceutical industry. This software allows for individual user access control and reduces human errors, thereby boosting productivity in quality assurance laboratories. The system has received accolades for its environmentally friendly manufacturing methods, highlighting Waters' commitment to sustainability. The new software will be available for use starting August 2025.
Read more →WATWaters améliore le logiciel du système HPLC Alliance iS, établissant ainsi un nouveau standard pour la traçabilité de bout en bout et l'intégrité des données Résumé de l'actualité Premier système HPLC intelligent de l'industrie à fournir une vérification de l'accès de l'utilisateur authentifié sur l'écran...
Waters Corporation has announced the release of version 2.0 of its HPLC Alliance iS system software. This update offers complete end-to-end traceability and enhanced data security for the pharmaceutical industry. The integration of user authentication improves compliance while reducing human errors by up to 40%. The software will be available from August 2025 and has also received sustainability certifications, emphasizing the company's commitment to environmentally friendly practices.
Read more →WATWaters établit une nouvelle référence en matière de robustesse et de sensibilité pour les laboratoires à haut débit avec le spectromètre de masse Xevo TQ Absolute XR 73e Conférence ASMS sur la spectrométrie de masse et les sujets associés - Waters Corporation (NYSE:WAT) a annoncé aujourd'hui le lancement du...
Waters Corporation has launched the Xevo TQ Absolute XR mass spectrometer at the 73rd ASMS Conference, setting a new standard for mass spectrometry sensitivity and robustness. This advanced instrument offers enhanced performance that surpasses its predecessor, making it especially suitable for pharmaceutical and environmental analysis. The Xevo TQ Absolute XR is designed to optimize operational efficiency while reducing energy consumption and environmental footprint. It is now available for order, promising significant operational benefits for laboratories engaged in sensitive trace analysis.
Read more →WATWaters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer 73rd ASMS Conference on Mass Spectrometry and Allied Topics – Waters Corporation (NYSE:WAT) today announced the launch of the Xevo™ TQ Absolute XR...
Waters Corporation announced the launch of the Xevo TQ Absolute XR Mass Spectrometer at the 73rd ASMS Conference. This new mass spectrometer is designed to provide high sensitivity and robustness for pharmaceutical quantitation and PFAS detection. It boasts a six-fold increase in performance robustness, reduced environmental footprint, and significant operational efficiencies. The product is already receiving positive feedback from users in the bioanalytical field, highlighting its ability to deliver high-quality results for complex analyses.
Read more →WATWaters establece un nuevo estándar de sensibilidad con el espectrómetro de masas Xevo TQ Absolute XR -Waters establece un nuevo estándar de robustez y sensibilidad para laboratorios de alto rendimiento con el espectrómetro de masas Xevo TQ Absolute...
Waters Corporation has launched the Xevo TQ Absolute XR mass spectrometer, enhancing sensitivity and robustness for high-performance laboratories. This new spectrometer surpasses its predecessor in performance metrics, particularly for pharmaceutical quantitation and PFAS detection. It consumes 50% less energy and occupies less space, making it an environmentally friendly option. The innovative design is aimed at meeting the evolving regulatory needs in analytical laboratories, ensuring minimal downtime and high-quality results.
Read more →WATWaters stellt BioResolve Protein A Affinity Columns zur Beschleunigung der Antikörper-Titermessung vor und steigert damit die Prozessflexibilität und Chargenqualität Die Waters Corporation (NYSE:WAT) gab heute die Einführung der BioResolve™ Protein A Affinity Columns mit MaxPeak™ Premier Technology bekannt, die...
Waters Corporation has launched the BioResolve Protein A Affinity Columns featuring MaxPeak Premier Technology, aiming to enhance titer measurement accuracy and speed up bioprocessing. This innovative product represents Waters' first foray into affinity chromatography and promises a seven-fold improvement in sensitivity compared to leading products. The columns are designed for integration with size exclusion chromatography to allow simultaneous analysis of titer concentrations and aggregate evaluations. With this launch, Waters aims to expedite the development of safe and effective biotherapeutics.
Read more →WATWaters lance les colonnes d'affinité BioResolve pour la protéine A afin d'accélérer la mesure du titre des anticorps et améliorer l'agilité des processus et la qualité des lots Waters Corporation (NYSE:WAT) a annoncé aujourd'hui le lancement des colonnes d'affinité BioResolve™ pour la protéine A avec la technologie MaxPeak™...
Waters Corporation has launched the BioResolve affinity columns for Protein A, featuring MaxPeak technology that promises precise antibody titer measurements. This marks a significant milestone for the company, aimed at addressing unmet needs in large molecule separation. The new columns facilitate faster access to results in upstream bioprocessing and enable quick method optimization essential for biologics development. These advancements are expected to support the timely availability of life-saving therapies for patients.
Read more →WATWaters presenta las columnas de afinidad de proteína A BioResolve - Waters presenta las columnas de afinidad de proteína A BioResolve para acelerar la medición del título de anticuerpos, mejorando la agilidad del...
Waters Corporation has launched BioResolve protein A affinity columns, enhancing the measurement of antibody titles and improving bioprocessing agility. The columns, which utilize MaxPeak Premier technology, offer sensitivity seven times better than market leaders, enabling accurate results with less sample. This innovation aims to speed up therapeutic development and streamline workflows for customers involved in biopharmaceuticals. These columns are now available in various formats for immediate orders.
Read more →WATWaters Introduces BioResolve Protein A Affinity Columns to Accelerate Antibody Titer Measurement, Enhancing Process Agility and Batch Quality Waters Corporation (NYSE:WAT) today announced the launch of the BioResolve™ Protein A Affinity Columns with MaxPeak™ Premier Technology, providing...
Waters Corporation has announced the launch of its BioResolve Protein A Affinity Columns featuring MaxPeak Premier Technology. This innovation addresses bottlenecks in biotherapeutic development by providing precise antibody titer measurements and significantly improving workflow efficiency. The columns offer a 7x increase in sensitivity compared to competitors, allowing for reliable quantification at lower concentrations. Designed for integration into various LC systems, these columns aim to expedite the testing and development process for antibody-based drugs.
Read more →WATWaters acquiert Halo Labs, élargissant ainsi son portefeuille d'analyses biologiques Waters Corporation (NYSE:WAT) a annoncé aujourd'hui l'acquisition de Halo Labs™, un innovateur de technologies d'imagerie spécialisées pour détecter, ...
Waters Corporation has announced its acquisition of Halo Labs, which specializes in imaging technologies for detecting and analyzing particles in therapeutic products. The innovative Aura platform from Halo Labs will complement Waters' Wyatt Technology portfolio, boosting capabilities in particle analysis critical for therapies like CAR-T. This acquisition aims to enhance Waters' offerings in large molecule development and quality control, positioning the company as a leader in specialized analytical technologies. Additionally, it is expected to have a negligible impact on the company's financial results over the next year.
Read more →WATWaters erwirbt Halo Labs und erweitert damit das Portfolio für biologische Analysen Die Waters Corporation (NYSE:WAT) hat heute die Übernahme von Halo Labs™ bekannt gegeben, einem innovativen Anbieter von spezialisierten...
Waters Corporation has announced the acquisition of Halo Labs, which offers specialized imaging technologies for detecting and identifying particles in therapeutic products. The move aims to enhance Waters' portfolio and strengthen its leadership in analytical and biotechnological testing for large molecule therapies. Halo Labs' technology facilitates the analysis of a variety of particle types at low sample volumes, which can improve safety and efficiency in therapeutic development. The acquisition is expected to have a minor impact on Waters' financials in the next 12 months.
Read more →WATWaters adquiere Halo Labs y amplía su cartera de análisis biológicos Waters Corporation (NYSE:WAT) anunció hoy que ha adquirido Halo Labs™, un innovador en tecnologías de imágenes especializadas para detectar,...
Waters Corporation announced the acquisition of Halo Labs, a company specializing in imaging technologies for detecting impurities in therapeutic products. The incorporation of Halo Labs' Aura technology will enhance Waters' capabilities in particle analysis, aiding in the development and manufacturing of therapies. The acquisition is projected to have a minimal impact on Waters' financial performance in the upcoming year. This strategic move aims to bolster Waters' position within the rapidly evolving biopharmaceutical landscape and support advancements in cell therapies.
Read more →WATWaters Acquires Halo Labs, Expanding Biological Analysis Portfolio Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify,...
Waters Corporation has announced the acquisition of Halo Labs, a company specializing in imaging technologies for detecting particles in therapeutic products. This acquisition aims to enhance Waters' portfolio, particularly in the development and quality assurance of large molecule therapies such as CAR T-cells. The integration of Halo Labs' technologies is expected to provide earlier insights during therapy development and improve manufacturing safety. The impact on Waters' income statement from this acquisition is anticipated to be negligible over the next 12 months.
Read more →WATCaspar Tudor, Head of Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports First Quarter 2025 Financial Results Highlights Strong start to the year as first quarter 2025
Waters Corporation (NYSE: WAT) announced its financial results for the first quarter of 2025, reporting sales of $662 million, a 4% increase year-over-year. The diluted earnings per share were $2.03, also up from $1.72 in the prior year. The company has raised its guidance for full-year 2025, anticipating continued growth driven by strong market demand, particularly in pharmaceuticals and innovative products. The results exceeded expectations, showcasing the resilience of Waters Corporation in a dynamic external environment.
Read more →WATWaters Corporation (NYSE: WAT) Reports First Quarter 2025 Financial Results Highlights Strong start to the year as first quarter 2025 sales of $662 million landed at the high-end of guidance range; grew 4% as reported and 7%...
Waters Corporation (NYSE: WAT) has reported a strong financial performance for the first quarter of 2025, achieving sales of $662 million, which represents a 4% increase compared to the same period last year. The company also raised its full-year guidance for both sales and non-GAAP earnings per share, citing robust growth in their instrument sales and strength in the pharmaceutical market. CEO Dr. Udit Batra highlighted the effective operational actions taken to mitigate impacts from external factors. Overall, the company anticipates delivering strong earnings growth throughout the year.
Read more →WATWaters Integrates Multi-Angle Light Scattering Detectors with Empower Software for Improved Biologics Quality Control and Simplified Regulatory Compliance Waters Corporation (NYSE:WAT) today announced that its Empower™ Software now supports biologics data acquisition and quality control (QC) analysis...
Waters Corporation announced the integration of Multi-Angle Light Scattering (MALS) detectors with its Empower Software, which will enhance quality control processes for biologics. This advancement enables the management of critical quality attributes and simplifies regulatory compliance, potentially saving labs up to six months in software validation time. The new capabilities will be available for peptide and protein workflows starting July 2025, streamlining testing and improving data accuracy in the development of life-saving therapies.
Read more →WATWaters integra detectores de dispersión de luz multiángulo con el software Empower - Waters integra detectores de dispersión de luz multiángulo con el software Empower para mejorar el control de calidad de los productos biológicos y ...
Waters Corporation announced the integration of its Empower software with multi-angle light scattering (MALS) detectors, enhancing the quality control process for biopharmaceuticals. This innovation simplifies regulatory compliance and reduces validation time for customers by up to six months. The software's ability to detect high molecular weight species previously undetectable supports more accurate quality control testing. Set for availability in July 2025, this solution is expected to improve productivity and data precision in biotherapeutics analysis.
Read more →WATWaters integriert Mehrwinkel-Lichtstreuungsdetektoren mit Empower Software für verbesserte Qualitätskontrolle von Biologika und vereinfachte Einhaltung gesetzlicher Vorschriften Die Waters Corporation (NYSE:WAT) gab heute bekannt, dass ihre Empower™ Software jetzt die Erfassung von Biologika-Daten und die Analyse der...
Waters Corporation has announced the integration of their Empower™ software with multi-angle light scattering detectors to enhance quality control of biologics. This development allows biopharmaceutical laboratories to manage critical quality attributes more effectively and improves compliance with regulatory requirements. The integration is expected to reduce software validation time significantly, ultimately benefiting the efficiency of biotherapeutic development. This service update will be available for peptide and protein workflows in July 2025.
Read more →WATWaters intègre des détecteurs de diffusion de lumière multi-angles au logiciel Empower afin d'améliorer le contrôle de la qualité des produits biologiques et simplifier la conformité réglementaire. Waters Corporation (NYSE:WAT) a annoncé aujourd'hui que son logiciel Empower™ prenait désormais en charge l'acquisition de données biologiques et...
Waters Corporation announced that its Empower™ software will now support the acquisition of biological data and quality control analysis from multi-angle light scattering (MALS) instruments. This integration will enhance the quality management capabilities for biopharmaceutical laboratories and streamline compliance with regulatory authorities. The new features aim to reduce the analysis time by 20% and significantly cut down the software validation timeframe. The integration of DAWN™ and miniDAWN™ detectors will enable the measurement of critical quality attributes for biologics in a more efficient manner.
Read more →WATWaters Corporation Schedules First Quarter 2025 Earnings Conference Call Waters Corporation (NYSE:WAT) will hold its Q1 2025 financial results conference call on Tuesday, May 6th, 2025 at 8:00 a.m. Eastern Time. A live...
Waters Corporation (NYSE: WAT) has announced its Q1 2025 earnings conference call scheduled for May 6, 2025. The call will take place at 8:00 a.m. Eastern Time, with a live webcast available via the Waters Investor Relations website. A replay of the webcast will be accessible until June 3, 2025. This event highlights the company's commitment to maintaining communication with its investors regarding financial performance.
Read more →WATWaters Expands Alliance iS Bio HPLC Product Line with Photodiode Array Detector to Enhance Spectral Insights for Biopharma Development & QC Waters Corporation (NYSE:WAT) today announced the expansion of the Alliance™ iS Bio HPLC product line with integrated photodiode array (PDA)...
Waters Corporation has expanded its Alliance™ iS Bio HPLC product line by introducing a system with integrated photodiode array (PDA) detection. This advancement is aimed at improving spectral analysis for biopharmaceutical development and quality control. The new system simplifies complex analyses, reduces operational errors, and enhances sensitivity significantly. Additionally, the platform has received sustainability recognition for its eco-friendly manufacturing practices.
Read more →WATWaters Corporation to Present at the Leerink Partners Global Healthcare Conference Waters Corporation (NYSE: WAT) announced that Udit Batra Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at...
Waters Corporation (NYSE: WAT) has announced that CEO Udit Batra, Ph.D., will take part in a fireside chat at the upcoming Leerink Partners Global Healthcare Conference on March 11, 2025. The event will be accessible via a live webcast, with a replay available for 90 days afterward. This participation underscores Waters' commitment to engaging with the healthcare community and showcasing their advancements in analytical technologies.
Read more →WATCaspar Tudor, Head of Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2024 Financial Results Highlights Fourth Quarter 2024 Sales of $8
Waters Corporation (NYSE: WAT) reported its financial results for Q4 and full-year 2024, showing a 6% increase in fourth quarter sales to $873 million. The company achieved a 13% increase in non-GAAP earnings per share, despite facing foreign exchange challenges. Strong growth was noted in the pharmaceutical and academic markets, with full-year expectations for 2025 including a projected sales growth of 2.5% to 5.0%. CEO Dr. Udit Batra emphasized successful execution of strategic initiatives and the company’s solid positioning for future growth.
Read more →WATWaters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2024 Financial Results Highlights Fourth Quarter 2024 Sales of $873 million exceeded high-end of guidance range, grew 6% as reported and 8% in constant currency Instruments ...
Waters Corporation reported its fourth quarter and full-year 2024 financial results, achieving $873 million in sales for Q4 2024, marking a 6% increase from Q4 2023. The company experienced notable growth in the pharmaceutical market, with sales rising by 8% as reported. Despite foreign exchange headwinds impacting earnings, Waters anticipates modest sales growth for 2025. The leadership emphasized a robust operational execution and strategic initiatives paving the way for future growth.
Read more →WATDas Waters ElectroForce Apex 1 Instrument bietet mehr Vielseitigkeit, Einfachheit und Schnelligkeit bei der mechanischen Prüfung von modernen Polymermaterialien Zusammenfassung der Nachrichten: Bietet mehr Vielseitigkeit und datengestützte Erkenntnisse mit einem um 43 % größeren Motorhubbereich (100 mm),1 und ...
Waters Corporation has launched the ElectroForce Apex 1, a mechanical testing instrument optimized for versatility, speed, and user-friendliness. This device is designed to perform precise tensile and fatigue tests on advanced polymers and composite materials, significantly improving the testing process. It boasts a motor stroke range that is at least 43% greater than competitors, allowing for a broader array of materials to be tested and providing test results up to 30% faster. With new automated software capabilities, the ElectroForce Apex 1 enhances workflow efficiency while ensuring reliability and safety in material selection and performance evaluation.
Read more →WATL'instrument Waters ElectroForce Apex 1 offre une polyvalence, une simplicité et une rapidité accrues dans le domaine des essais mécaniques sur les matériaux polymères avancés Résumé du communiqué : Il offre une plus grande polyvalence et une meilleure connaissance des données grâce à une course du moteur augmentée de 43 %...
Waters Corporation has launched the ElectroForce Apex 1, an advanced mechanical testing instrument designed to enhance versatility, speed, and ease of use for testing high-performance polymers and composites. The instrument increases the motor stroke by 43%, enabling laboratories to conduct a wider variety of tests and improving efficiency. Its user-friendly features and intelligent data acquisition system further enhance its functionality. The ElectroForce Apex 1 is now available for order.
Read more →WATWaters ElectroForce Apex 1 Instrument Offers Increased Versatility, Simplicity, and Speed to Mechanical Testing of Advanced Polymer Materials News Summary: Offers increased versatility and data-driven insights with 43% greater motor stroke range (100 mm),1 expanding testing to more...
Waters Corporation has launched its new ElectroForce Apex 1 Mechanical Testing Instrument, designed for advanced polymer and composite testing. This instrument features a motor stroke range that is 43% greater than competitors, allowing for enhanced versatility in material testing. Additionally, it offers improved speed, with testing times reduced by up to 30%. New software capabilities aim to streamline operations and reduce the likelihood of operator errors, making it a valuable tool for industries that require precise material characterization.
Read more →WATWaters lanza el instrumento ElectroForce Apex 1 para pruebas mecánicas de materiales poliméricos avanzados - El instrumento ElectroForce Apex 1 de Waters ofrece mayor versatilidad, simplicidad y velocidad para las pruebas mecánicas de materiales...
Waters Corporation has launched the ElectroForce Apex 1 mechanical testing instrument, designed for advanced polymer materials. This instrument enhances versatility, speed, and user-friendliness for accurate tensile and fatigue testing. With an improved motor range and capabilities, it allows for faster testing and reduces developmental costs by identifying weaknesses early in the material selection and design process. The Apex 1 is now available for order, catering to a growing demand for reliable mechanical testing in various high-performance applications.
Read more →WATInnovative Waters TGA Smart-Seal Pans Enable Lower Cost, More Efficient Benchtop Analysis of Atmosphere-Sensitive Materials Waters Corporation (NYSE:WAT) today announced the launch of TGA Smart-Seal™ Pans from its TA Instruments Division. The innovative, self-opening...
Waters Corporation has launched the TGA Smart-Seal Pans from its TA Instruments Division, designed for analyzing atmosphere-sensitive samples in a cost-effective manner. These innovative pans allow for reliable thermogravimetric analysis without the complexity and high costs associated with glovebox setups. By utilizing a self-opening mechanism, the pans ensure airtight conditions during sample analysis, enhancing accuracy and efficiency. Available globally, this product aims to meet the growing demand for speed and precision in various research applications, including materials science and pharmaceuticals.
Read more →WATLes nouvelles cuvettes TGA Smart-Seal de Waters permettent de réduire les coûts et d'améliorer l'efficacité de l'analyse en laboratoire des matériaux sensibles à l'atmosphère. Résumé du communiqué : Nouveau produit exclusif permettant aux laboratoires d'analyser les matériaux sensibles à l'atmosphère utilisés pour...
Waters Corporation has launched the TGA Smart-Seal cuvettes designed for thermogravimetric analyzers, enabling the analysis of air-sensitive materials without needing a glove box. These cuvettes utilize a unique temperature-sensitive shape memory alloy to automatically open at around 55°C, preserving sample integrity. By eliminating the need for a glove box, laboratories can save on installation and maintenance costs while being able to operate multiple TGA instruments simultaneously. The TGA Smart-Seal cuvettes are now available worldwide.
Read more →WATLas innovadoras bandejas Waters TGA Smart-Seal permiten un análisis de laboratorio más eficiente -Las innovadoras bandejas Waters TGA Smart-Seal permiten un análisis de laboratorio más eficiente y de menor coste de materiales sensibles a la...
Waters Corporation has launched the TGA Smart-Seal Pans, designed for efficient analysis of air-sensitive samples in labs. This innovation allows for accurate thermogravimetric analysis without the need for controlled atmosphere compartments, reducing both complexity and costs. Users, including researchers at reputable institutions, report enhanced productivity and reduced operational burden. The TGA Smart-Seal Pans are now available for purchase globally.
Read more →WATInnovative Waters TGA Smart-Seal-Pans ermöglichen kostengünstigere und effizientere Benchtop-Analysen von atmosphärensensiblen Materialien Zusammenfassung der Nachrichten: Neues und firmeneigenes Produkt, mit dem Labore atmosphärenempfindliche Materialien, die zur Entwicklung von...
Waters Corporation has introduced TGA Smart-Seal™ Pans, designed to facilitate the analysis of air-sensitive samples in Thermogravimetric Analyzers (TGA) without the need for a glovebox. This innovation promises reliable and accurate data, effectively reducing operation costs and complexity for laboratories. The self-opening feature and airtight design enable the safe preparation of sensitive materials, offering significant productivity benefits. The TGA Smart-Seal-Pans are now available globally, aiming to enhance research capabilities in various fields.
Read more →WATWaters Corporation Schedules Fourth Quarter 2024 Earnings Conference Call Waters Corporation (NYSE:WAT) will hold its Q4 2024 financial results conference call live on Wednesday, February 12th, 2025 at 8:00 a.m. Eastern...
Waters Corporation (NYSE: WAT) has announced a scheduled conference call for its fourth quarter 2024 financial results, which will take place on February 12, 2025. The event will be broadcast live on the company's Investor Relations website, with a replay available until March 12, 2025. Waters Corporation is known for its leadership in analytical instruments and software, having operated for over 65 years in various scientific fields.
Read more →WATJ.P. Morgan 43rd Annual Healthcare Conference Udit Batra, Ph.D. President & CEO
During the J.P. Morgan 43rd Annual Healthcare Conference, Udit Batra, Ph.D., President & CEO of Waters Corporation, presented forward-looking statements regarding the company’s financial and operational performance. Highlights included a strong business model serving regulated markets and projected growth rates in the analytical instruments sector. However, Batra cautioned that actual results may differ due to various uncertainties, including the impacts of the recent Wyatt acquisition and market dynamics. The presentation emphasized Waters' strategic focus on growth and customer satisfaction in its core business areas.
Read more →WATWaters Corporation to Host Investor Day on March 5, 2025 Waters Corporation (NYSE:WAT) announced that it will host an Investor Day on Wednesday, March 5th, 2025, in New York City, starting at 8:30 AM ET....
Waters Corporation has announced it will host an Investor Day on March 5, 2025, in New York City. The event will include presentations from senior management outlining business achievements, strategic priorities, and future plans for shareholder value creation. A Q&A session is planned, allowing attendees to engage directly with the management team. The event will also have a live webcast for remote participation, ensuring broad access to the company's vision and initiatives.
Read more →WATWaters Corporation intègre l'indice Dow Jones Sustainability pour la quatrième année consécutive Waters Corporation (NYSE: WAT) a annoncé son entrée dans l'indice Dow Jones Sustainability North America (DJSI North America) pour la quatrième année ...
Waters Corporation has announced its inclusion in the Dow Jones Sustainability North America Index for the fourth consecutive year, reflecting its strong sustainability practices. The company's achievements include surpassing its greenhouse gas reduction targets two years early and enhancing its community representation. Additionally, Waters is committed to science-based targets for future emissions reductions and has invested in environmentally friendly manufacturing facilities, demonstrating a solid commitment to long-term stakeholder value.
Read more →WATWaters Corporation zum vierten Mal in Folge in den Dow Jones Sustainability Index aufgenommen Wie Waters Corporation (NYSE: WAT) mitteilte, ist das Unternehmen aufgrund seiner unternehmensweiten Nachhaltigkeitspraktiken im vierten Jahr in...
Waters Corporation has been included in the Dow Jones Sustainability North America Index for the fourth consecutive year, showcasing its commitment to sustainability. The recognition follows the company's achievement of reducing greenhouse gases two years earlier than planned. Waters also highlighted its efforts in enhancing societal representation and long-term stakeholder value through good governance. Recently, the company opened a new environmentally sustainable manufacturing facility in the UK, further strengthening its commitment to sustainability.
Read more →WATWaters Corporation nombrado en el Índice de Sostenibilidad Dow Jones por cuarto año consecutivo Waters Corporation (NYSE: WAT) anunció que ha sido incluida en el Índice Dow Jones de Sostenibilidad de Norteamérica (DJSI North America) por cuarto...
Waters Corporation has announced its inclusion in the Dow Jones Sustainability Index for North America for the fourth year in a row, reflecting its strong sustainability practices. The company noted significant achievements, such as achieving its greenhouse gas reduction target two years early and advancing STEM education initiatives. Waters highlighted its commitment to sustainability with recent investments in LEED certified and environmentally-efficient manufacturing facilities. The company continues to strive for improved governance and long-term stakeholder value.
Read more →WATWaters Corporation Named to Dow Jones Sustainability Index for the Fourth Consecutive Year Waters Corporation (NYSE: WAT) announced it has been named to the Dow Jones Sustainability North America Index (DJSI North America) for the fourth...
Waters Corporation has announced its inclusion in the Dow Jones Sustainability North America Index for the fourth consecutive year. This recognition is based on the company's strong commitment to sustainability and successful initiatives, including achieving greenhouse gas reduction targets early. Waters continues to enhance stakeholder value through effective governance and has made significant progress in environmental responsibility. The company recently opened a new manufacturing facility in the UK, reflecting its ongoing dedication to sustainable practices.
Read more →WATWaters Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference Waters Corporation (NYSE:WAT) announced that Udit Batra Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at...
Waters Corporation announced that CEO Udit Batra will participate in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. This participation underscores the company's commitment to engaging with investors and sharing insights on its business operations. A live webcast will be available, ensuring that interested parties can access the discussion. The replay of the event will also be available for 90 days.
Read more →WATWaters Highlights Continued Progress Towards Sustainability Commitments News Summary: Exceeded its goal of reducing Scope 1 and 2 greenhouse gas emissions by 36% from a 2016 baseline, two years ahead of schedule. Invested ...
Waters Corporation has announced significant progress towards its sustainability commitments as per its 2024 report. The company exceeded its target of reducing Scope 1 and 2 greenhouse gas emissions by 36% from its 2016 baseline, achieving this goal two years ahead of time. Additionally, Waters has been recognized with 14 awards for its environmental, social, and governance efforts, including being listed among Barron's 2024 100 Most Sustainable Companies. These initiatives include increased renewable energy procurement and support for STEM education in underserved communities.
Read more →WATWaters Corporation to Present at the Evercore 2024 HealthCONx Conference Waters Corporation (NYSE:WAT) announced that Udit Batra Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at...
Waters Corporation (NYSE:WAT) has announced that its CEO, Udit Batra, will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on December 4, 2024. This event will feature a live webcast available on the company's Investor Relations website, with a replay accessible for 90 days. Waters continues to affirm its position as a leader in analytical instruments across various sciences.
Read more →WATWaters Corporation Opens State-of-the-Art Precision Manufacturing Facility in Longbridge, UK Waters Corporation (NYSE:WAT) announced the official opening of its new 45,000 square foot manufacturing facility at the Longbridge Business Park in...
Waters Corporation has officially opened a new 45,000 square foot manufacturing facility at Longbridge Business Park in the West Midlands. This significant investment enhances the company's machining capacity and triples existing operations, allowing for the production of critical components for its mass spectrometry systems. The facility also highlights Waters' commitment to sustainability, achieving a BREEAM Very Good standard and an Energy Performance Certificate rating of 'A'. This new site is positioned to bolster Waters' manufacturing capabilities in the region.
Read more →WATWaters New Software Delivers Lab-Centric Business Intelligence and Enables Confident Audit-Readiness News Summary: waters_connect™ Data Intelligence software provides laboratories with comprehensive business intelligence on their chromatographic data ...
Waters Corporation has launched its waters_connect Data Intelligence software, designed to enhance business intelligence for laboratories handling chromatographic data. This software aims to improve data quality and integrity, thereby reducing potential delays in product releases and regulatory audits. By offering advanced analytical insights and eliminating costly manual data processes, it enables laboratories to respond more efficiently and improve readiness for audits. The software is set to be available for orders in December 2024 and will work seamlessly with existing Empower CDS instances.
Read more →WATCaspar Tudor, Head of Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports Third Quarter 2024 Financial Results Highlights Sales of $740 million exceeded guidance, grew
Waters Corporation (NYSE: WAT) reported its financial results for Q3 2024, showcasing strong sales of $740 million, a 4% increase from the previous year. The company's earnings per share also rose, contributing to a positive outlook. Sales growth is expected to be impacted by currency translation, leading to a decrease in projected sales for the full year. However, new product adoption and improved customer spending trends have bolstered confidence in the company's long-term prospects.
Read more →WATWaters Corporation (NYSE: WAT) Reports Third Quarter 2024 Financial Results Highlights Sales of $740 million exceeded guidance, grew 4% as reported and 4% in constant currency Instruments returned to growth; recurring revenue ...
Waters Corporation has reported its financial results for the third quarter of 2024, highlighting sales of $740 million, marking a 4% increase from the previous year. The company saw growth in the instruments segment, particularly in liquid chromatography for pharmaceutical and industrial markets. Despite an overall positive performance, Waters has raised concerns about headwinds from unfavorable foreign exchange rates. The company has also adjusted its full-year guidance for both sales and non-GAAP EPS upwards, demonstrating confidence in its future outlook.
Read more →WATWaters New Bioseparations Tools Accelerate and Improve Development of RNA-based Vaccines and Therapies Using LC-MS Analysis News Summary: Waters new LC-MS grade reagents, enzymes, and software simplify large molecule RNA analysis to accelerate and improve development of...
Waters Corporation has launched new bioseparation tools designed to enhance the development of large molecule RNA-based therapeutics using liquid chromatography-mass spectrometry (LC-MS). These tools simplify the confirmation of RNA sequences and modifications, improving efficiency in the development process. They are aimed at accelerating the development of innovative therapies such as CRISPR and mRNA therapeutics, thereby addressing significant medical challenges. The new products include sample preparation enzymes, reagents, and software that support compliance-ready analyses in therapeutic development.
Read more →WATNew Waters Discovery Core Rheometer Brings the Power of Rheology to Routine Quality Control Testing News Summary: Easy-to-use, compact analyzer makes rheological insights more accessible to quality testing laboratories and material production...
Waters Corporation has launched the TA Instruments Discovery Core Rheometer, a modern analyzer designed for routine quality control in manufacturing. Capable of testing various materials, it features an easy-to-use touchscreen interface along with self-guided training. This new instrument provides superior performance while requiring less space, addressing an unmet need in the marketplace. The rheometer is orderable now, with global availability expected by Q1 2025.
Read more →WATWaters Corporation Schedules Third Quarter 2024 Earnings Conference Call Waters Corporation (NYSE:WAT) will hold its Q3 2024 financial results conference call live on Friday, November 1st, 2024 at 8:00 a.m. Eastern Time. A ...
Waters Corporation (NYSE: WAT) has announced that it will hold a conference call on November 1, 2024, to discuss its financial results for the third quarter of 2024. The call is scheduled to take place at 8:00 a.m. Eastern Time, and a live webcast will be available via the company's Investor Relations website. A replay of the webcast will be accessible until November 29, 2024, providing stakeholders an opportunity to review the financial outcomes.
Read more →WATWaters Corporation Appoints Heather Knight to Board of Directors
Waters Corporation has appointed Heather Knight to its Board of Directors, effective August 14, 2024. Knight is currently the Executive Vice President and Group President for Medical Products and Therapies at Baxter International, bringing nearly three decades of experience in business and leadership within the pharmaceutical and medical device industries. Both the Chair of the Board and the CEO expressed their enthusiasm about her joining, highlighting her operational excellence and global experience as crucial to advancing the company's growth strategy.
Read more →WATWaters Corporation Appoints Heather Knight to Board of Directors Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight...
Waters Corporation has appointed Heather Knight to its Board of Directors, effective August 14, 2024. Knight, currently an Executive Vice President at Baxter International, is recognized for her extensive experience in the pharmaceutical and medical device sectors. The leadership at Waters Corporation is optimistic that her expertise will enhance board oversight and contribute positively to their growth strategy. Knight expressed her excitement about joining Waters at a pivotal time for the company.
Read more →WATCaspar Tudor, Head of Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports Second Quarter 2024 Financial Results Highlights Sales of $709 million exceeded guidance on a
Waters Corporation reported a sales figure of $709 million for the second quarter of 2024, marking a 4% decline compared to the previous year. Despite this decrease, the company exceeded its financial guidance for both top-line and bottom-line results. The leadership anticipates a return to growth in the second half of 2024, attributing confidence to ongoing product innovation. Some sectors, particularly pharmaceuticals and academia, experienced notable sales declines during the quarter.
Read more →WATWaters Corporation (NYSE: WAT) Reports Second Quarter 2024 Financial Results Highlights Sales of $709 million exceeded guidance on a reported basis, declined 4% as reported and 4% in organic constant currency GAAP EPS of...
Waters Corporation (NYSE: WAT) reported its financial results for the second quarter of 2024, showing sales of $709 million, a 4% decrease from the previous year. While the company exceeded sales guidance, both GAAP and non-GAAP earnings per share (EPS) fell compared to Q2 2023. Sales declines were noted across all global regions, attributed to foreign exchange impacts and operational challenges. However, management remains optimistic about future growth, highlighting a robust product pipeline and promising third quarter sales forecasts.
Read more →WATWaters New Rapid Screening-DSC Enables Up to 24x Faster Thermal Stability Testing at Ultra-Low Sample Volumes for Antibody Drugs News Summary: Reduces sample volume requirements by 25x through use of advanced microfluidic technologies while increasing throughput up to 24x...
Waters Corporation has launched the TA Instruments Rapid Screening-Differential Scanning Calorimeter (RS-DSC), designed for high-throughput thermal stability testing of antibody drugs. This new instrument significantly enhances testing efficiency by allowing up to 24 simultaneous measurements while reducing sample volume needs by 25 times. The RS-DSC aims to meet the increasing demand for faster stability testing in biopharmaceutical development by providing a convenient and precise alternative to current technologies. The product is now available globally through Waters Corporation's TA Instruments Division.
Read more →WATWaters Corporation Schedules Second Quarter 2024 Earnings Conference Call Waters Corporation (NYSE:WAT) will hold its Q2 2024 financial results conference call live on Wednesday, July 31st, 2024 at 8:00 a.m. Eastern Time. A ...
Waters Corporation (NYSE: WAT) has announced a conference call to discuss its Q2 2024 financial results, set for July 31, 2024, at 8:00 a.m. Eastern Time. Investors will be able to access a live webcast on the Waters Investor Relations website, with a replay available until August 28, 2024. This event highlights Waters' ongoing commitment to transparency and its engagement with stakeholders.
Read more →WATWaters Sets New Standards for High Resolution Performance and Speed with Xevo MRT Mass Spectrometer News Summary: Waters Xevo™ MRT Mass Spectrometer employs next-generation multi-reflecting time-of-flight technology to deliver class-leading...
Waters Corporation has launched the Xevo MRT mass spectrometer during the 72nd ASMS Conference, setting new standards for high resolution and speed in mass spectrometry. This next-generation system integrates multi-reflecting time-of-flight and hybrid quadrupole time-of-flight technologies, aimed at facilitating large-scale epidemiological studies. It offers impressive specifications, including 100,000 FWHM resolution at a 100 Hz scan speed and less than 500 ppb mass accuracy, promising to enhance drug discovery processes significantly. The Xevo MRT mass spectrometer is expected to be available for order by the second half of 2024.
Read more →WATWaters Becomes First Liquid Chromatography Column Provider to Receive My Green Lab ACT Ecolabel Certification News Summary: Waters becomes the first vendor to obtain ACT™ Ecolabel Certification for 42 of its liquid chromatography columns, providing...
Waters Corporation has announced that it is the first liquid chromatography column provider to receive the My Green Lab ACT Ecolabel Certification for 42 of its products. This recognition marks a significant achievement in promoting sustainability within laboratory practices. The ACT Ecolabel aims to assist scientists in making environmentally conscious product choices. Waters has also made strides in enhancing the sustainability of its chromatography columns through innovative packaging designs.
Read more →WATWaters Corporation to Present at the Jefferies 2024 Healthcare Conference Waters Corporation (NYSE:WAT) announced that Udit Batra Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at...
Waters Corporation (NYSE: WAT) has announced that CEO Udit Batra, Ph.D., will participate in a fireside chat at the Jefferies 2024 Healthcare Conference on June 5th, 2024. This event provides an opportunity for the company to engage with investors and discuss its ongoing initiatives. A live webcast of the event will be available, along with a replay for 90 days. Waters Corporation is recognized for its analytical instruments and software, serving various sectors for over 65 years.
Read more →WATWaters ACQUITY QDa II Mass Detector Delivers Wider Range of Chemical Analysis within Cost-Effective, Lower Energy Instrument News Summary: ACQUITY™ QDa™ II Mass Detector enhances confidence in routine compound identification using the specificity of mass analysis to boost...
Waters Corporation has launched the ACQUITY QDa II Mass Detector, an advanced mass detection instrument that offers a broader mass range and improved efficiency. It is designed for seamless integration into laboratory workflows while enhancing compound analysis capabilities across various sectors. The new detector reduces energy consumption and boasts recognition for sustainability. This product aims to support scientists by providing reliable results quickly, which is crucial in sectors like pharmaceuticals where delays can impact patient outcomes.
Read more →WATCaspar Tudor, Head of Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports First Quarter 2024 Financial Results Highlights Sales of $637 million at the high-end of guida
Waters Corporation (NYSE: WAT) reported its financial results for the first quarter of 2024, with sales of $637 million, reflecting a 7% decrease from $685 million in the same quarter last year. The company noted challenges due to unfavorable foreign exchange rates impacting both sales and diluted earnings per share, which were down to $1.72 from $2.38 year-over-year. Despite these declines, management highlighted that quarterly revenues were at the high end of the guidance, attributing some growth to recent acquisitions, while sales in the pharmaceutical, industrial, and academic markets experienced notable decreases. Looking ahead, Waters projects a further reduction in sales growth for the upcoming quarter and anticipates non-GAAP earnings per share for the full year to be between $11.75 and $12.05.
Read more →WATWaters Corporation (NYSE: WAT) Reports First Quarter 2024 Financial Results Highlights Sales of $637 million at the high-end of guidance, declined 7% as reported and 9% in organic constant currency GAAP EPS of $1.72; earnings ...
Waters Corporation reported a first quarter 2024 revenue of $637 million, reflecting a 7% decrease compared to the same period last year. The company's diluted GAAP earnings per share also fell to $1.72, down from $2.38 in the first quarter of 2023. Despite these declines, Waters achieved sales at the high end of its guidance and reported margin expansion. Looking ahead, the company anticipates full-year sales growth of 0.0% to +2.0%, while non-GAAP EPS for 2024 is projected to be between $11.75 and $12.05.
Read more →WATWaters Accelerates the Development of Gene-based Therapeutics with New GTxResolve Premier SEC Columns News Summary: New line of GTxResolve™ Premier SEC Columns provide higher sensitivity, resolution, and throughput to accelerate the development of...
Waters Corporation has launched its GTxResolve Premier Size Exclusion Chromatography (SEC) 1000Å 3-micron Columns, designed to enhance the development of gene-based therapeutics. The new columns feature advanced packing materials and MaxPeak Premier High-Performance Surface technology, which offer higher sensitivity, resolution, and throughput. This innovation aims to meet the growing demands for mRNA and viral vector therapies, facilitating faster approvals and better drug safety assessments. The GTxResolve columns are now available globally and promise improved separation efficiency and reduced sample consumption.
Read more →WATWaters Corporation Schedules First Quarter 2024 Earnings Conference Call Waters Corporation (NYSE:WAT) will hold its Q1 2024 financial results conference call live on Tuesday, May 7th, 2024 at 8:00 a.m. Eastern Time. A...
Waters Corporation has announced that it will hold its Q1 2024 financial results conference call on May 7th, 2024, at 8:00 a.m. Eastern Time. Investors can access a live webcast of the event through the company's Investor Relations website. Additionally, a replay of the webcast will be available until June 4th, 2024. Waters Corporation is recognized for its contributions to analytical instruments and has a global presence in multiple sectors.
Read more →WATWaters Launches Alliance iS Bio HPLC System to Help Biopharma QC Labs Increase Efficiency and Reduce Errors News Summary: New Alliance™ iS Bio High Performance Liquid Chromatography (HPLC) System helps biopharmaceutical QC laboratories boost efficiency and...
Waters Corporation has launched the Alliance iS Bio HPLC System, designed to enhance efficiency in biopharma quality control laboratories. This new system features advanced bio-separation technology and intelligent instrument functionalities that can reduce common errors by up to 40%. It incorporates bio-inert design elements and pairs with Waters' other products for improved chromatography testing and compliance. The system is now available globally and aims to help QC labs meet stringent compliance requirements while boosting productivity.
Read more →WATEffizienz steigern, Fehler reduzieren: Waters bringt Alliance™ iS Bio HPLC-System auf den Markt, um biopharmazeutische QC-Labore zu unterstützen Das neue Alliance™ iS Bio Hochleistungsflüssigkeitschromatografie-(HPLC-)System hilft biopharmazeutischen Quality Control-(QC)Laboren, ihre Effizienz ...
Waters Corporation has launched the Alliance™ iS Bio HPLC-System aimed at improving the efficiency of biopharmaceutical quality control laboratories. This new system integrates advanced bio-separation technology with smart device features, helping to reduce common operational errors significantly. It facilitates faster product release times by addressing daily operational challenges and complying with evolving regulations. The device is now available globally, offering seamless integration with liquid chromatography instruments from Waters and other manufacturers.
Read more →WATWaters Streamlines and Expedites PFAS Testing with Innovative Oasis Dual-Phase Cartridges News Summary: Waters Oasis™ Dual-phase PFAS Analysis Cartridges simplify sample preparation for EPA 1633 testing for analysis of PFAS concentrations...
Waters Corporation has launched its new Oasis WAX/GCB and GCB/WAX cartridges designed for PFAS analysis, which simplify sample preparation according to EPA 1633 standards. These dual-phase cartridges reduce the two-step process of traditional sample preparation, cutting down approximately 30 minutes per sample batch, and are quality-controlled for low residual PFAS. This product is timely as increasing regulatory scrutiny on PFAS testing is expected, driven by major regulations under the EPA and European bodies. The cartridges are now available for worldwide order, supporting the growing demand for efficient PFAS testing solutions.
Read more →WATWaters Advances Battery Electrode Design and Performance Analysis with New Rheo-IS Accessory News Summary: New Rheo-Impedance Spectroscopy (Rheo-IS) accessory enables battery scientists to better assess electrode slurry composition quality...
Waters Corporation has launched a new accessory, the Rheo-IS, for its Discovery Hybrid Rheometers, aimed at improving the analysis of battery electrode slurries. This accessory facilitates simultaneous electrical impedance and rheological measurements, allowing researchers to assess slurry quality under real-world conditions. The enhanced capability is expected to accelerate electrode material development and boost battery production efficiency. The accessory integrates easily with existing equipment and offers improved data quality through automation.
Read more →WATWaters Announces Seamless HPLC/UPLC Data Bridge for Light Scattering, Integrating Essential Instruments for Large Molecule Characterization News Summary: Waters now enables seamless connectivity between its liquid chromatography (LC) systems and multi-angle light-scattering instruments...
Waters Corporation has launched HPLC CONNECT software, a new platform designed to enhance connectivity between its liquid chromatography systems and multi-angle light-scattering instruments. This software aims to simplify the characterization of large molecules crucial for biopharmaceutical innovations, including complex proteins and gene therapies. By streamlining data synchronization, it significantly reduces labor and human error while improving the reliability of generated data. HPLC CONNECT is now available worldwide and supports various Waters LC systems.
Read more →WATWaters Corporation to Present at the TD Cowen 44th Annual Health Care Conference Waters Corporation (NYSE:WAT) announced that Udit Batra Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the TD...
Waters Corporation (NYSE: WAT) announced that its CEO, Udit Batra, will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on March 4, 2024. The event will include a live webcast for investors, which will also be available for replay for 90 days. This participation underscores the company's commitment to transparency and engagement with stakeholders in the health sector.
Read more →WATCaspar Tudor, Head of Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2023 Financial Results Highlights Fourth Quarter 2023 Sales of $8
Waters Corporation reported financial results for the fourth quarter and full year of 2023, showing a decline in sales and earnings per share. Q4 sales were $819 million, down 4.5% from $859 million in the previous year, and annual sales totalled $2,956 million, a decrease of 0.5%. The company noted challenges in its pharmaceutical and industrial markets, but highlighted gains in recurring revenues and the impact of its Wyatt acquisition on sales. Looking ahead, Waters provided guidance for modest sales growth in 2024 amid continuing currency headwinds.
Read more →WATWaters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2023 Financial Results Highlights Fourth Quarter 2023 Sales of $819 million declined 4.5% as reported and 8% in organic constant currency, in line with guidance Operational ...
Waters Corporation reported financial results for the fourth quarter and full year of 2023, highlighting a decline in sales. The fourth-quarter sales were $819 million, down from $859 million in the previous year, aligning with previously provided guidance. Additionally, the company witnessed a decrease in overall sales for the fiscal year, affected by unfavorable foreign exchange rates. Despite these challenges, the acquisition of Wyatt contributed positively to sales, revealing some resilience in recurring revenue streams.
Read more →WATWaters Corporation Schedules Fourth Quarter 2023 Earnings Conference Call Waters Corporation (NYSE:WAT) will hold its Q4 2023 financial results conference call live on Tuesday, February 6th, 2024 at 8:00 a.m. Eastern Time....
Waters Corporation is set to hold its Q4 2023 financial results conference call on February 6th, 2024, at 8:00 a.m. Eastern Time. A live webcast will be accessible on the Waters Investor Relations website, and a replay will be provided until March 5th, 2024. This event reflects Waters Corporation's commitment to maintaining open communication with its shareholders.
Read more →WATJ.P. Morgan 42nd Annual Healthcare Conference Udit Batra, Ph.D. President & CEO
At the J.P. Morgan 42nd Annual Healthcare Conference, Waters Corporation's President & CEO, Udit Batra, Ph.D., highlighted the company's robust business model and positioned it for future growth in attractive markets. The firm presents a total addressable market of $12 billion, with a strong focus on high-volume regulated applications across various sectors. However, Batra cautioned about the uncertainties and risks linked to recent acquisitions, particularly the acquisition of Wyatt Technology, which could affect future financial performance.
Read more →WATWaters Corporation to Present at the 42nd Annual J.P. Morgan Healthcare Conference Waters Corporation (NYSE:WAT) announced that Udit Batra Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 42nd ...
Waters Corporation (NYSE: WAT) will have its CEO, Udit Batra, participate in a fireside chat at the upcoming 42nd Annual J.P. Morgan Healthcare Conference. The event is scheduled for January 8, 2024. A live webcast will be available for investors and the general public, ensuring broad access to the discussions on the company's innovations and strategic direction.
Read more →WATWaters Earns Sustainability Designation from My Green Lab for Xevo TQ Absolute System News Summary: My Green Lab awards ACT label to the Waters Xevo™ TQ Absolute system, providing independent validation for its sustainable...
Waters Corporation has received the ACT label for its Xevo TQ Absolute mass spectrometer from My Green Lab, marking a significant milestone in sustainability recognition. The system is highlighted for its compact design and superior analytical capabilities, particularly in detecting low levels of PFAS compounds, thereby addressing increasing regulatory requirements. The Xevo TQ Absolute system reportedly uses 50% less energy and generates 50% less heat than other comparable systems, along with using recycled materials. This designation reflects Waters' commitment to promoting sustainable laboratory practices.
Read more →WATWaters Corporation Named to Dow Jones Sustainability Index for the Third Consecutive Year Waters Corporation (NYSE: WAT) announced it has been named to the Dow Jones Sustainability North America Index (DJSI North America) for the third...
Waters Corporation (NYSE: WAT) has been recognized for the third consecutive year in the Dow Jones Sustainability North America Index, reflecting its strong ESG practices. The evaluation was based on the S&P Global Corporate Sustainability Assessment, where Waters outperformed industry averages in Environmental, Social, Governance, and Economic criteria. CEO Dr. Udit Batra emphasized the company's commitment to sustainable practices, including reducing emissions and increasing renewable energy use. Additionally, Waters is fostering diversity in science-related professions through educational programs for underrepresented students.
Read more →WATWaters Corporation Board of Directors Named 2024 Public Company Board of the Year by National Association of Corporate Directors New England Chapter Waters Corporation (NYSE: WAT) today announced that its Board of Directors has been named 2024 Public Company Board of the Year by the National...
Waters Corporation has announced that its Board of Directors has been named the 2024 Public Company Board of the Year by the National Association of Corporate Directors (NACD) New England Chapter. The award honors outstanding corporate governance and leadership among directors in the region. Waters' Chairman Dr. Flemming Ornskov and President/CEO Dr. Udit Batra will accept the award on April 24, 2024. The recognition underscores the board's commitment to shareholder value, diversity, and transparency.
Read more →WATWaters Corporation Opens New State-of-the-Art Global Capability Center in Bengaluru, India Waters Corporation (NYSE: WAT) inaugurated its new Global Capability Center (GCC), a strategic investment to accelerate technology adoption,...
Waters Corporation has inaugurated its new Global Capability Center in Bengaluru, India, representing a strategic investment aimed at accelerating technology adoption and innovation. The facility, costing US$16 million, will employ over 300 people in various technology and development roles, moving operations from outsourcing to in-house. The center is positioned to serve as a hub for talent development, operational efficiency, and enhanced capabilities to support global customers. This initiative highlights India's importance as a growing market for Waters Corporation.
Read more →WATWaters Earns Top Score in Human Rights Campaign Foundation's 2023-2024 Corporate Equality Index News Summary: Waters recognized for its companywide policies and active commitment to LGBTQIA+ workplace equality and inclusion, scoring 100 on the...
Waters Corporation has been awarded a score of 100 on the Human Rights Campaign's 2023-2024 Corporate Equality Index for its policies and practices related to LGBTQ+ workplace equality. This recognition reflects the company's commitment to cultivating an inclusive environment where LGBTQIA+ employees can thrive. The company has introduced enhanced health benefits for gender transition and has partnered with organizations focused on supporting LGBTQIA+ communities. This marks the second consecutive year that Waters has achieved this recognition.
Read more →WATWaters Corporation to Present at the Evercore ISI HealthCONx 2023 Health Care Conference Waters Corporation (NYSE: WAT) announced that Udit Batra Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the...
Waters Corporation (NYSE: WAT) announced that CEO Udit Batra, Ph.D., will participate in a fireside chat at the Evercore ISI HealthCONx 2023 Health Care Conference. The event is set to take place in Miami on November 30th, 2023. A live webcast of the conference will be available on Waters' Investor Relations website, along with a replay for 90 days afterwards. This engagement highlights Waters' continued commitment to investor relations and transparency in its operations.
Read more →WATWATERS 2023 ESG REPORT HIGHLIGHTS CONTINUED PROGRESS TOWARDS SUSTAINABILITY COMMITMENTS News Summary: Waters makes strong progress on its goal to reduce greenhouse gas emissions 35% by 2025 through greater use of renewable/low-carbon...
Waters Corporation has released its 2023 Environmental, Social, and Governance (ESG) report, showcasing significant progress in its sustainability efforts. The report details the company's achievements, including a commitment to reduce greenhouse gas emissions by 35% by 2025 and enhancements in product sustainability. Additionally, Waters received multiple awards for its ESG initiatives, reflecting its commitment to social responsibility and sustainability in operations and products.
Read more →WATCaspar Tudor, Head of Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports Third Quarter 2023 Financial Results Highlights Sales of $712 million grew less than 1% as rep
Waters Corporation announced its Q3 2023 financial results, reporting sales of $712 million, which grew less than 1% year-over-year. The company experienced a 4% increase in sales for pharmaceutical applications in the U.S. and Europe, but a significant decline in sales in China affected overall performance. The recent Wyatt acquisition contributed 4% to sales growth, while the earnings per share showed a decrease compared to the same quarter in the previous year. The company's guidance for full-year organic sales growth indicates a decline, and they anticipate unfavorable foreign exchange impacts.
Read more →WATWaters Corporation (NYSE: WAT) Reports Third Quarter 2023 Financial Results Highlights Sales of $712 million grew less than 1% as reported and declined 4% in organic constant currency Low single-digit organic constant...
Waters Corporation reported its third quarter 2023 financial results, revealing sales of $712 million, which grew less than 1% year-over-year but declined 4% in organic constant currency. While the pharmaceutical applications showed better-than-expected growth in the U.S. and Europe, challenges in China significantly affected overall performance. The company noted a positive contribution from the Wyatt acquisition, increasing sales by 4%. Financial guidance indicates anticipated declines in organic sales growth, with projections suggesting a reported sales growth range between -1% to flat for the year.
Read more →WATWaters Corporation Announces Business Unit Leadership Transition Waters Corporation (NYSE:WAT) today announced that Jonathan ( Jon ) Pratt has decided to step down from his role as Senior Vice President of the...
Waters Corporation announced that Jonathan Pratt will step down from his role as Senior Vice President of the Waters Division to pursue an external opportunity. Effective immediately, Christos Ross will serve as the Interim Senior Vice President while continuing to manage global operations. The company has initiated a search for a permanent successor. Leadership emphasized confidence in a smooth transition due to Ross's prior experience with the organization and contributions to its strategy.
Read more →WATWaters Corporation Announces Business Unit Leadership Transition Jonathan Pratt to Step Down to Pursue an External Opportunity Christos Ross Named Interim Senior Vice President of the Waters Divisio
Waters Corporation announced that Jonathan Pratt will step down as Senior Vice President of the Waters Division to pursue an external opportunity. Christos Ross, currently the Senior Vice President of Global Operations, has been named Interim Senior Vice President of the Waters Division as the company searches for a permanent successor. The transition is expected to be smooth, with support from the leadership team, and highlights the internal talent available within the company.
Read more →WATWaters Accelerates Oligonucleotide Bioanalysis with the Launch of OligoWorks™ SPE Workflow and Kits News Summary: Delivers up to 2x[i] higher oligonucleotide recovery from biofluids with improved LC-MS sensitivity and reproducibility to support...
Waters Corporation has launched OligoWorks SPE Kits aimed at improving bioanalytical quantitation of therapeutic oligonucleotides. These kits promise up to 2x higher oligonucleotide recovery from biofluids and enhance the sensitivity of LC-MS analyses. They are designed to address challenges in sample preparation, potentially accelerating drug development timelines for oligonucleotide therapies. The innovation includes enzyme-enhanced pretreatment for improved mass spectrometer compatibility, allowing for better analytical performance.
Read more →WATWaters Corporation Schedules Third Quarter 2023 Earnings Conference Call Waters Corporation (NYSE: WAT) will hold its Q3 2023 financial results conference call live on Tuesday, November 7th, 2023 at 8:00 a.m. Eastern Time. ...
Waters Corporation has announced its Q3 2023 earnings conference call scheduled for November 7th, 2023, at 8:00 a.m. Eastern Time. The live event will be accessible via a webcast on the company's Investor Relations website, with a replay available until November 21, 2023. The announcement highlights Waters Corporation's transparency and commitment to maintaining investor relations. With over 60 years in the analytical instruments industry, the company continues to engage its global audience effectively.
Read more →WATL'instrument ZetaStar de Waters augmente la vitesse et la sensibilité des mesures de diffusion de la lumière pour les thérapies biologiques Résumé de l'article : Le nouvel instrument ZetaStar™ pour l'analyse des nanoparticules du portefeuille Wyatt Technology™ réunit trois techniques de...
Waters Corporation a lancé l'instrument ZetaStar, qui combine plusieurs techniques de diffusion de la lumière pour analyser les nanoparticules. Cet instrument permet des mesures dynamiques et statiques simultanées, offrant ainsi des résultats plus rapides et précis pour le développement de thérapies biologiques. Il est conçu pour augmenter l'efficacité des laboratoires en utilisant de très faibles volumes d'échantillons. La chambre d'analyse innovante et l'interface tactile simplifient l'utilisation et la collecte de données.
Read more →WATEl instrumento Waters ZetaStar aumenta la sensibilidad de las mediciones de dispersión de luz - El instrumento Waters ZetaStar aumenta la velocidad y la sensibilidad de las mediciones de dispersión de luz para terapias biológicas Resumen de...
Waters Corporation ha lanzado su nuevo instrumento DynaPro ZetaStar, diseñado para mejorar las mediciones de dispersión de luz en el análisis de nanopartículas. Este dispositivo permite realizar mediciones dinámicas y estáticas de manera simultánea, proporcionando datos más rápidos y precisos, esenciales para el desarrollo de terapias biológicas complejas. Con características como un diseño de celda de flujo único y una interfaz de pantalla táctil, el ZetaStar optimiza el trabajo en laboratorios de investigación y desarrollo biofarmacéutico. Su capacidad de realizar mediciones con volúmenes de muestra extremadamente bajos destaca su aplicabilidad en varias áreas de investigación, incluyendo terapias génicas y ciencia de materiales.
Read more →WATMessgerät ZetaStar von Waters steigert Geschwindigkeit und Empfindlichkeit von Lichtstreuungsmessungen für biologische Therapien Zusammenfassung der Neuigkeiten: Das neue Messgerät ZetaStar™ aus dem Portfolio von Wyatt Technology™ für die Nanopartikel-Analyse kombiniert drei...
Die Waters Corporation hat das neue ZetaStar-Messgerät vorgestellt, das innovative Lichtstreutechniken kombiniert, um die Analyse von Nanopartikeln zu optimieren. Mit der Fähigkeit, mehrere Messungen gleichzeitig durchzuführen, steigert es die Effizienz und Empfindlichkeit in der biologischen Therapieentwicklung. Das Gerät erleichtert es Wissenschaftlern, wichtige Parameter zu ermitteln und unterstützt unter anderem die Entwicklung stabiler Therapien in den Bereichen Gentherapie und Impfstoffe. Die Einführung des ZetaStar stellt einen bedeutenden Schritt in der Zusammenarbeit zwischen Waters und Wyatt Technology dar.
Read more →WATWaters ZetaStar Instrument Boosts Speed and Sensitivity of Light Scattering Measurements for Biological Therapies News Summary: New Zeta Star™ instrument for nanoparticle analysis from Wyatt Technology™ portfolio combines three light scattering techniques into a...
Waters Corporation has launched the DynaPro ZetaStar instrument, a versatile device for nanoparticle analysis combining multiple light scattering techniques. This instrument increases measurement speed and sensitivity while minimizing sample volume requirements, thus aiding biopharma development. It enhances laboratory efficiency with features like an autosampler and a user-friendly touchscreen interface. Designed for the growing demands of the biopharmaceutical industry, the ZetaStar instrument aims to improve the development of complex therapies, including those related to gene therapy and vaccines.
Read more →WATWaters bringt neue Walk-up-Lösungen auf den Markt, die die Analyse von biologischen Arzneimitteln und Zellkulturmedien weiter vereinfachen Zusammenfassung der Neuigkeiten: Die überarbeitete Waters™ OneLab™-Software bietet neue, benutzerfreundliche Walk-up-Lösungen, die das BioAccord™...
Waters Corporation has launched new walk-up solutions designed to simplify the preparation and analysis of biological samples. These innovations can eliminate the need for shipping bioreactor samples to central labs, consequently speeding up upstream bioprocess development by up to six weeks. Enhanced by the updated Waters OneLab software, these solutions enable bioprocess engineers to efficiently collect essential data directly from the bioreactor. The integration of LC-MS systems, like BioAccord, facilitates ease of use for less experienced operators, thereby promoting better understanding and shorter development timelines.
Read more →WATWaters Launches New Walk-up Solutions that Further Simplify the Analysis of Biologic Drug Product and Cell Culture Media News Summary: Updated Waters™ OneLab™ software creates new, easy-to-use walk-up solutions integrating Waters BioAccord™ LC-MS system and Andrew+™...
Waters Corporation has launched new bioprocess walk-up solutions designed to simplify the analysis of biologic drug products and cell culture media. The solutions leverage updated OneLab software and the BioAccord LC-MS system, allowing bioprocess engineers to perform analyses directly from bioreactor samples. This innovation can significantly reduce development timelines and improve process understanding, leading to more efficient manufacturing. The solutions are now available worldwide and support seamless data transfer from Sartorius Ambr Multi-Parallel Bioreactors.
Read more →WATWaters présente de nouvelles solutions accessibles qui simplifient davantage l'analyse des produits biologiques et des milieux de culture cellulaire Résumé de l'article : Le nouveau logiciel Waters™ OneLab™ permet de créer de nouvelles solutions accessibles faciles à utiliser, en intégrant le...
Waters Corporation has unveiled new accessible bioprocess solutions designed to simplify sample preparation and analysis. The OneLab software enables quicker data acquisition and streamlining of workflows, potentially shortening development timelines by up to six weeks. Additionally, it allows less experienced LC-MS users to generate critical quality attributes directly in the lab. These innovations aim to enhance the robustness of manufacturing processes and ultimately reduce pharmaceutical costs for patients.
Read more →WATWaters lanza nuevas soluciones que simplifican aún más el análisis de productos biológicos -Waters lanza nuevas soluciones que simplifican aún más el análisis de productos biológicos y medios de cultivo celular Resumen de la noticia: El...
Waters Corporation has launched innovative bioprocess solutions aimed at enhancing the analysis of biological samples and cell culture media. These solutions eliminate the need for sending samples to central labs, potentially accelerating bioprocess development by up to six weeks compared to traditional methods. With a combination of updated OneLab automation software and advanced LC-MS systems, bioprocess engineers can now efficiently capture high-quality data with ease. The new offerings are now available globally and promise to improve manufacturing processes and reduce costs in pharmaceutical production.
Read more →WATWaters Corporation to Present at the Bank of America Global Healthcare Conference 2023 Waters Corporation (NYSE:WAT) announced that Udit Batra Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Bank ...
Waters Corporation announced that Udit Batra, Ph.D., its President and CEO, will participate in a fireside chat at the Bank of America Global Healthcare Conference in London on September 13, 2023. The event is scheduled for 8:20 AM Eastern Time and will be available via a live webcast. This participation emphasizes Waters' ongoing engagement with the healthcare investment community.
Read more →WATWaters Corporation (NYSE: WAT) Reports Second Quarter 2023 Financial Results Waters Corporation (NYSE: WAT) today announced its financial results for the second quarter of 2023....
Waters Corporation reported its financial results for Q2 2023, showing a 4% increase in sales year-over-year, driven by growth in the U.S. and Europe. However, the pharmaceutical market experienced a decline in sales, and overall sales in Asia decreased significantly, particularly in China. The company anticipates a challenging third quarter with expected organic constant currency sales growth declining by 4% to 2%. Despite these challenges, the acquisition of Wyatt is expected to contribute positively to future growth.
Read more →WATCaspar Tudor, Head of Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports Second Quarter 2023 Financial Results Highlights Sales of $741 million grew 4% as reported and
Waters Corporation reported its second quarter 2023 financial results, showcasing a 4% increase in sales to $741 million compared to the previous year. While there was a notable decline in sales in the pharmaceutical sector and regions like Asia, the acquisition of Wyatt and strong sales growth in U.S. and European markets contributed positively. The company also updated its full-year financial guidance, projecting modest growth amid challenging market conditions.
Read more →WATWaters Launches XBridge Premier GTx BEH SEC Columns for Gene Therapy Applications News Summary: Reduces the cost of gene therapies by using 3-10x less sample than other methodsi while generating faster results and more drug...
Waters Corporation has launched new XBridge Premier GTx BEH SEC columns designed to enhance the analysis and cost-effectiveness of gene therapies, particularly adeno-associated viral (AAV) vectors. These columns reportedly double the measurement speed of AAV potency and safety, while using significantly less sample compared to conventional methods. The benefits of these columns include streamlined processes for formulation studies, regulatory support, and quality control in gene therapy development. Avid Bioservices has noted the enhanced capabilities of their analytical methods using these new columns.
Read more →WATWaters Corporation Schedules Second Quarter 2023 Earnings Conference Call Waters Corporation (NYSE:WAT) will hold its Q2 2023 financial results conference call live on Wednesday, August 2nd, 2023, at 8:00 a.m. Eastern Time. ...
Waters Corporation has announced that it will conduct its Q2 2023 earnings conference call on August 2, 2023, at 8:00 a.m. Eastern Time. The event aims to inform investors about the company's financial performance. A live webcast will be accessible through Waters' Investor Relations website, with a replay available until at least August 16, 2023. Waters has established itself as a leader in analytical instruments and has a significant global footprint.
Read more →WATWaters Corporation and Princeton University Announce Multi-Year Research Collaboration Waters Corporation (NYSE: WAT) announced a multi-year research collaboration with Princeton University that will enable scientists, faculty, and...
Waters Corporation has entered a multi-year research collaboration with Princeton University, aiming to solve complex challenges in biochemistry and materials science. This partnership will unite academic researchers and industry experts to develop innovative solutions, including projects that focus on novel purification media to advance drug discovery. The collaboration promises to enrich education and foster research innovation within both institutions. Princeton's expertise in bioengineering will be crucial to the initiatives outlined in this agreement.
Read more →WATWaters Corporation Named to U.S. News & World Report's 2023-2024 Best Companies to Work For U.S. News & World Report, the global authority in rankings and consumer advice, has named Waters Corporation (NYSE:WAT) one of the 2023-2024 Best...
Waters Corporation (NYSE: WAT) has been named one of the Best Companies to Work For by U.S. News & World Report for 2023-2024. This prestigious recognition highlights the company's commitment to employee satisfaction based on various factors such as work-life balance, opportunities for professional development, and inclusivity. With over 8,200 employees globally, Waters has also earned accolades for its sustainability initiatives and commitment to workplace equality. The selection for this list was based on extensive evaluations, ensuring recognition for companies that prioritize employee needs.
Read more →WATWaters and Sartorius Expand Collaboration to Deliver Comprehensive Bioanalytics for Downstream Biomanufacturing Waters Corporation (NYSE: WAT) and Sartorius announced a new collaboration to develop integrated analytical solutions for downstream...
Waters Corporation and Sartorius have expanded their collaboration to develop integrated analytical solutions for downstream biomanufacturing. This partnership enhances their previous agreement focused on upstream bioprocessing analytics. The collaboration aims to provide bioprocess engineers with real-time analytical data, improving yields and reducing waste during the drug production process. The integration of Waters' chromatography system with Sartorius' chromatography platform is expected to streamline quality checks, significantly impacting production efficiency.
Read more →WATWaters y Sartorius amplían su colaboración - Waters y Sartorius amplían su colaboración para ofrecer bioanálisis completos para la fabricación de productos biológicos en etapas posteriores...
Waters Corporation and Sartorius have expanded their collaboration to develop integrated analytical solutions for later-stage biomanufacturing. This enhancement will improve data access for bioprocess engineers, potentially increasing yields, reducing waste, and lowering production costs. The integration of Waters' PATROL system with Sartorius' BioSMB system is expected to revolutionize real-time analytics in biomanufacturing, ultimately benefiting drug production timelines and quality. Both companies highlight the importance of timely analytics in achieving these objectives.
Read more →WATWaters und Sartorius erweitern ihre Zusammenarbeit zur Bereitstellung umfassender Bioanalytik für die nachgelagerte Bioproduktion Nachrichtenübersicht: Integration der Mehrsäulenchromatographie im Prozessmaßstab von Sartorius mit der prozessanalytischen Technologie von Waters,...
Waters Corporation and Sartorius have expanded their collaboration to enhance integrated analytical solutions for bioproduction. The partnership focuses on developing technologies that allow for real-time analysis, which can improve yields and reduce waste in downstream production processes. By integrating Waters' UltraPerformance Liquid Chromatography with Sartorius' BioSMB platform, the collaboration aims to provide bioprocess engineers with better access to analytical data. This could lead to significant time savings and improvements in product quality during the manufacturing of biological drugs.
Read more →WATWaters Takes Targeted, Quantitative Imaging to the Next Level with New DESI Source for the Xevo TQ Absolute System American Society for Mass Spectrometry (ASMS) -- Waters Corporation (NYSE:WAT) today launched the industry's first targeted imaging mass spectrometer ...
Waters Corporation has unveiled the first targeted imaging mass spectrometer, integrating its Xevo TQ Absolute system with a new DESI XS source. This innovative instrument boasts five times the sensitivity and speed compared to existing systems, allowing for precise drug targeting within biological tissues. The new capabilities will aid scientists in efficiently evaluating drug effects and meeting stringent regulatory standards in their research efforts. Waters continues to lead advancements in analytical technologies for life sciences applications.
Read more →WATWaters Boosts Resolution and Triples Scan Speed of SELECT SERIES MRT for Metabolomics and MS Imaging News Summary: New resolution enhancement mode (REM) for Waters' multi-reflecting time-of-flight (MRT) mass spectrometer leads to greater specificity...
Waters Corporation has announced significant enhancements to its SELECT SERIES MRT System, which now features a 50% increase in resolution and a threefold improvement in scan speed. These enhancements are designed to improve the analysis of blood, urine, and tissue samples in metabolomics and mass spectrometry imaging. The updates allow research scientists to achieve greater specificity in identifying analytes, potentially accelerating the translation of research into clinical applications. Notable researchers have expressed optimism about the impact of these advancements on their studies in cancer diagnostics and drug distribution.
Read more →WATWaters et Sartorius élargissent le champ de leur collaboration afin d'offrir une bioanalyse complète pour la fabrication en aval de produits biologiques Résumé de l'article : Intégration de la chromatographie multicolonnes à l'échelle des procédés de Sartorius à la technologie analytique des procédés...
Waters Corporation and Sartorius have expanded their partnership to develop integrated analytical solutions for downstream biomanufacturing. This collaboration enhances the capabilities of Waters' UPLC system and Sartorius' Resolute BioSMB platform, allowing bioprocess engineers to access comprehensive analytical data. The integration is expected to improve production yields, reduce costs, and streamline quality control processes. By enabling real-time analytics, the partnership can significantly cut down the time taken for quality checks in the production process.
Read more →WATWaters Corporation to Present at the Jefferies 2023 Healthcare Conference Waters Corporation (NYSE:WAT) announced that Udit Batra Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the...
Waters Corporation (NYSE: WAT) announced that CEO Udit Batra will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on June 8, 2023. The event will be available via a live webcast on the company's Investor Relations website. This participation highlights Waters' commitment to engage with its investors and update them on corporate developments. The company, known for its innovations in analytical instruments, has a significant global presence with operations in over 35 countries.
Read more →WATWaters Corporation completa la adquisición del líder en dispersión de luz Wyatt Technology Waters™ Corporation (NYSE: WAT) ha anunciado hoy que ha completado la adquisición de Wyatt Technology, empresa pionera y líder reconocida en...
Waters Corporation has announced the completion of its acquisition of Wyatt Technology, a leader in light scattering instrumentation. This acquisition is expected to enhance Waters' capabilities in bioanalytical characterization for new modalities, particularly in the rapidly growing market for cell and gene therapies. It is anticipated that the deal will immediately increase Waters' revenue growth and profitability, with expected synergies of over $70 million annually by the fifth year post-acquisition. Waters aims for a smooth integration process to provide unmatched solutions for its global customers.
Read more →WATWaters Corporation acquiert le leader de la diffusion de la lumière Wyatt Technology Waters™ Corporation (NYSE : WAT) a annoncé aujourd'hui avoir finalisé l'acquisition de Wyatt Technology, un pionnier et un leader reconnu dans le...
Waters Corporation has finalized the acquisition of Wyatt Technology, a leader in light scattering instrumentation. This acquisition aims to enhance Waters' offerings in bioanalytical characterization, particularly for emerging therapies. The transaction is expected to benefit Waters' revenue growth and margin profile, with an estimated annual revenue synergy of over $70 million. Additionally, Waters anticipates an accretive effect on its adjusted earnings per share starting from the first quarter of 2024.
Read more →WATWaters Corporation Completes Acquisition of Light Scattering Leader Wyatt Technology Waters™ Corporation (NYSE: WAT) today announced it has completed its acquisition of Wyatt Technology, a pioneer and well-recognized leader in...
Waters Corporation has successfully completed the acquisition of Wyatt Technology, a leader in light scattering instrumentation. This acquisition aims to enhance Waters' capabilities in bioanalytical characterization, particularly for large molecule applications like cell and gene therapies. The deal is projected to generate significant revenue synergies and positively impact Waters' revenue growth and earnings. Company leadership anticipates a strong integration process with Wyatt's team, aiming to deliver advanced analytical solutions to clients globally.
Read more →WATWaters Corporation Completes Acquisition of Light Scattering Leader Wyatt Technology Milford, MA.
Waters Corporation has completed the acquisition of Wyatt Technology, a leader in light scattering instruments and services. This move is expected to enhance Waters' capabilities in bioanalytical characterization, particularly for new modalities like cell and gene therapies, projected to have a $1.8 billion market. The transaction is anticipated to be immediately accretive to revenue and earnings, while generating significant revenue synergies over the next five years. Dr. Udit Batra, President and CEO of Waters, noted the acquisition as a milestone for advancing the company's growth strategy.
Read more →WATWaters Corporation (NYSE: WAT) Reports First Quarter 2023 Financial Results Highlights First quarter sales of $685 million declined 1% as reported and grew 3% in constant currency Growth in broader Asia and Europe offset by...
Waters Corporation (NYSE: WAT) reported its first quarter 2023 financial results, revealing a 1% decrease in sales, totaling $685 million. While sales into the pharmaceutical market declined 7%, the company did report a 3% growth in constant currency. CEO Dr. Udit Batra highlighted a strong two-year growth rate of 9.4% and emphasized the launch of a new product, Alliance iS, as a significant advancement in the industry. Additionally, the upcoming acquisition of Wyatt Technology is expected to contribute positively to sales growth and margins.
Read more →WATCaspar Tudor, Head of Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports First Quarter 2023 Financial Results Highlights First quarter sales of $685 million declined 1
Waters Corporation (NYSE: WAT) reported its first-quarter financial results for 2023 on May 9, revealing a 1% decline in sales to $685 million compared to $691 million the previous year, although a 3% increase in constant currency was noted. The diluted earnings per share decreased to $2.38 from $2.62 in Q1 2022, mainly affected by foreign exchange headwinds. Notably, the company is optimistic about future growth driven by the launch of its new product Alliance iS and the anticipated acquisition of Wyatt Technology, which is expected to enhance revenues.
Read more →WATWaters Corporation Appoints Richard Fearon to Board of Directors
Waters Corporation announced the appointment of Richard Fearon to its Board of Directors, effective March 27, 2023. Fearon, the former Vice Chairman and Chief Financial and Planning Officer of Eaton Corporation, is expected to contribute to Waters' strategic growth and value creation. This appointment comes as Waters continues to expand its competitive position following the retirement of long-standing board member Edward Conard. The board will now consist of nine members, three of whom have been appointed in the last year.
Read more →WATCaspar Tudor, Head of Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports Fourth Quarter And Full-Year 2022 Financial Results Highlights Fourth quarter sales of $859 mi
Waters Corporation reported robust financial results for the fourth quarter and full year of 2022, with sales reaching $859 million and a notable increase in earnings per share. The company also announced plans to acquire Wyatt Technology Corporation for $1.36 billion, which is expected to bolster its growth strategy moving forward. Despite these achievements, sales in the pharmaceutical market experienced flat growth, and unfavorable foreign exchange conditions posed challenges to overall performance.
Read more →WATJ.P. Morgan 41st Annual Healthcare Conference Udit Batra, Ph.D. President & CEO
At the J.P. Morgan 41st Annual Healthcare Conference, Waters Corporation's President & CEO, Udit Batra, emphasized the company's strong execution and consistent revenue growth. The company reported a 14% increase in organic revenue growth year-over-year, underscoring its innovation and market resilience. However, Batra noted that forward-looking statements carry risks and uncertainties that could influence actual results, particularly in volatile markets.
Read more →WATWaters Corporation Appoints Dan Brennan and Mark Vergnano to Board of Directors
Waters Corporation Appoints Dan Brennan and Mark Vergnano to Board of Directors MILFORD, Mass. November 23, 2022 Waters Corporation (NYSE:WAT) today announced the appointment of Dan Brennan and Mark Vergnano, to its Board of Directors, effective November 23, 2022. Mr. Brennan c
Read more →WATCaspar Tudor, Head of Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports Third Quarter 2022 Financial Results Highlights Sales of $709 million grew 7% as reported and
Tudor, Head of Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports Third Quarter 2022 Financial Results Milford, Mass., November 1, 2022 - Waters Corporation (NYSE: WAT) today announced its financial results for the third quarter of 2022. Our team is con
Read more →WATCaspar Tudor, Head of Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports Second Quarter 2022 Financial Results Highlights Sales of $714 million grew 5% as reported and
Tudor, Head of Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports Second Quarter 2022 Financial Results Milford, Mass., August 2, 2022 Waters Corporation (NYSE: WAT) today announced its financial results for the second quarter of 2022. Our team s strong
Read more →WATAnalyst & Investor Day
2022 Analyst & Investor Day May 19, 2022 watersTM Caspar Tudor Head of Investor Relations watersTM waters watersTM Cautionary Statements This estimates. presentation For this contains purpose, forward-looking any statements statements that are not regarding statements future o
Read more →WATCaspar Tudor, Director, Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports First Quarter 2022 Financial Results Highlights Sales of $691 million grew 13% as reported a
Contact: Caspar Tudor, Director, Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports First Quarter 2022 Financial Results Milford, Mass., May 3, 2022 - Waters Corporation (NYSE: WAT) today announced its financial results for the first quarter of Our team
Read more →WATCaspar Tudor, Director, Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2021 Financial Results Fourth quarter sales of $836 million gre
Contact: Caspar Tudor, Director, Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2021 Financial Results Milford, Mass., February 1, 2022 - Waters Corporation (NYSE: WAT) today announced fourth quarter 2021 sales of $836 m
Read more →WATThis presentation contains forward-looking statements regarding future results and events. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Words such
Udit Batra, Ph.D. President & CEO January 10, 2022 J.P. Morgan 40th Annual Healthcare Conference Exhibit 99.1 This presentation contains forward-looking statements regarding future results and events. For this purpose, any statements that are not statements of historical fact
Read more →WATJohn Lynch, Vice President, Treasurer (508) 482-2314 Caspar Tudor, Manager, Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports Third Quarter 2021 Financial Results Sal
Lynch, Vice President, Treasurer (508) 482-2314 Caspar Tudor, Manager, Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports Third Quarter 2021 Financial Results Milford, Mass., November 2, 2021 Waters Corporation (NYSE: WAT) today announced third quarter 2
Read more →WATWaters Corporation Appoints John M. Ballbach to Board of Directors Dr. Michael J. Berendt to Retire from Waters Board
Waters Corporation Appoints John M. Ballbach to Board of Directors Dr. Michael J. Berendt to Retire from Waters Board MILFORD, Mass. October 6, 2021 Waters Corporation (NYSE:WAT) today announced the appointment of John M. Ballbach to its Board of Directors, effective October
Read more →WATJohn Lynch, Vice President, Treasurer (508) 482-2314 Caspar Tudor, Manager, Investor Relations (508) 482-2429 Waters Corporation (NYSE: WAT) Reports Second Quarter 2021 Financial Results Sa
Lynch, Vice President, Treasurer (508) 482-2314 Caspar Tudor, Manager, Investor Relations (508) Waters Corporation (NYSE: WAT) Reports Second Quarter 2021 Financial Results Milford, Mass., August 3, 2021 - Waters Corporation (NYSE: WAT) today announced second quarter 2021 sale
Read more →WATWaters Corporation Appoints Wei Jiang to Board of Directors
Waters Corporation Appoints Wei Jiang to Board of Directors MILFORD, Mass June 24, 2021 Waters Corporation (NYSE: WAT) today announced the appointment of Wei Jiang to its Board of Directors, effective July 14, 2021. Mr. Jiang currently serves as Executive Vice President and Pre
Read more →WATBryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Waters Corporation (NYSE: WAT) Reports First Quarter 2021 Financial Results Sales of $609 million grew 31% as reporte
Contact: Bryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Corporation (NYSE: WAT) Reports First Quarter 2021 Financial Results Milford, Mass., May 5, 2021 - Waters Corporation (NYSE: WAT) today announced first quarter 2021 sales of $609 million, a 31% i
Read more →WATWaters Corporation Continues Transformation with Planned Leadership Transitions NEWS SUMMARY: Amol Chaubal named Waters Chief Financial Officer Jonathan Pratt named Senior Vice President of new Waters Division Jianqing B
Waters Corporation Continues Transformation with Planned Leadership Transitions MILFORD, Mass April 21, 2021 Waters Corporation (NYSE: WAT) continues its transformation program with the announcement of several planned leadership appointments and executive retirements. Amol Cha
Read more →WATBryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2020 Financial Results Fourth Quarter 2020 Highli
Contact: Bryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2020 Financial Results Fourth Quarter 2020 Highlights Milford, Mass., February 2, 2021 - Waters Corporation (NYSE: WAT) today announc
Read more →WATThis presentation may contain "forward-looking" statements regarding future results and events. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Withou
Udit Batra President & CEO J.P. Morgan 39th Annual Healthcare Conference Exhibit 99.1 This presentation may contain "forward-looking" statements regarding future results and events. For this purpose, any statements that are not statements of historical fact may be deemed forwa
Read more →WATWaters Corporation Appoints Pearl S. Huang to Board of Directors
Waters Corporation Appoints Pearl S. Huang to Board of Directors MILFORD, Mass. Dec. 10, 2020 Waters Corporation (NYSE:WAT) today announced that Dr. Pearl S. Huang, President and CEO of Cygnal Therapeutics and venture partner at Flagship Pioneering, has been appointed as a Dire
Read more →WATWaters Corporation Announces CFO Transition Sherry Buck to Step Down as
Waters Corporation Announces CFO Transition Sherry Buck to Step Down as CFO, Effective December 31, 2020 Michael Silveira Appointed Interim CFO, Effective January 1, 2021 MILFORD, Mass December 3, 2020 Waters Corporation (NYSE:WAT) today announced that Sherry Buck will step do
Read more →WATBryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Waters Corporation (NYSE: WAT) Reports Third Quarter 2020 Financial Results Sales of $594 million grew 3% as reported
Contact: Bryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Waters Corporation (NYSE: WAT) Reports Third Quarter 2020 Financial Results Milford, Mass., October 27, 2020 - Waters Corporation (NYSE: WAT) today announced third quarter 2020 sales of $594 mill
Read more →WATBryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Waters Corporation (NYSE: WAT) Reports Second Quarter 2020 Financial Results Sales of $520 million declined 13% as re
Contact: Bryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Corporation (NYSE: WAT) Reports Second Quarter 2020 Financial Results Milford, Mass., July 28, 2020 Waters Corporation (NYSE: WAT) today announced second quarter 2020 sales of $520 million, a 13%
Read more →WATWaters Corporation Names Udit Batra President and Chief Executive Officer Announces Preliminary Second Quarter 2020 Sales
Waters Corporation Names Udit Batra President and Chief Executive Officer Announces Preliminary Second Quarter 2020 Sales MILFORD, Mass. July 15, 2020 Waters Corporation (NYSE:WAT) ( Waters or the Company ) today announced that Udit Batra, Ph.D. has been named the Company s Pr
Read more →WATWaters Corporation Announces CEO Succession Plan
Waters Corporation Announces CEO Succession Plan MILFORD, Mass. June 17, 2020 Waters Corporation (NYSE:WAT) today announced that the Company s Board of Directors and Christopher O Connell have mutually agreed that Mr. O Connell will step down as President, Chief Executive Offic
Read more →WATBryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Waters Corporation (NYSE: WAT) Reports First Quarter 2020 Financial Results Provides Update on COVID-19 Business Impa
Contact: Bryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Corporation (NYSE: WAT) Reports First Quarter 2020 Financial Results COVID-19 Business Impact and Response Plan Milford, Mass., April 28, 2020 - Waters Corporation (NYSE: WAT) today announced fi
Read more →WATBryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2019 Financial Results Fourth Quarter 2019 Highli
Contact: Bryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2019 Financial Results Fourth Quarter 2019 Highlights Milford, Mass., February 4, 2020 - Waters Corporation (NYSE: WAT) today announc
Read more →WATBryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Waters Corporation (NYSE: WAT) Reports Third Quarter 2019 Financial Results Sales of $577 million were flat as report
Contact: Bryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Corporation (NYSE: WAT) Reports Third Quarter 2019 Financial Results Milford, Mass., October 29, 2019 - Waters Corporation (NYSE: WAT) today announced third quarter 2019 sales of $577 million, wh
Read more →WATBryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Waters Corporation (NYSE: WAT) Reports Second Quarter 2019 Financial Results Sales of $599 million were flat as repor
Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Waters Corporation (NYSE: WAT) Reports Second Quarter 2019 Financial Results Milford, Mass., July 30, 2019 Waters Corporation (NYSE: WAT) today announced second quarter 2019 sales of $599 million, which were fla
Read more →WATBryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Waters Corporation (NYSE: WAT) Reports First Quarter 2019 Financial Results Sales of $514 million declined 3% as repo
Contact: Bryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Corporation (NYSE: WAT) Reports First Quarter 2019 Financial Results Milford, Mass., April 23, 2019 Waters Corporation (NYSE: WAT) today announced first quarter 2019 sales of $514 million, a 3% d
Read more →WATBryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full Year 2018 Financial Results Fourth Quarter 2018 Highli
Contact: Bryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Corporation (NYSE: WAT) Reports Fourth Quarter and Full Year 2018 Financial Results Fourth Quarter 2018 Highlights Milford, Mass., January 23, 2019 - Waters Corporation (NYSE: WAT) today announc
Read more →WATBryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Waters Corporation (NYSE: WAT) Reports Third Quarter 2018 Financial Results Sales of $578 million grew 2% as reported
Contact: Bryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Corporation (NYSE: WAT) Reports Third Quarter 2018 Financial Results Milford, Mass., October 23, 2018 Waters Corporation (NYSE: WAT) today announced third quarter 2018 sales of $578 million, a 2%
Read more →WATBryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Waters Corporation (NYSE: WAT) Reports Second Quarter 2018 Financial Results Sales of $596 million grew 7% as reporte
Contact: Bryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Corporation (NYSE: WAT) Reports Second Quarter 2018 Financial Results Milford, Mass., July 24, 2018 - Waters Corporation (NYSE: WAT) today announced second quarter 2018 sales of $596 million, a 7
Read more →WATBryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Waters Corporation (NYSE: WAT) Reports First Quarter 2018 Financial Results Sales of $531 million grew 7% as reported
Contact: Bryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Corporation (NYSE: WAT) Reports First Quarter 2018 Financial Results Mass., April 24, 2018 - Waters Corporation (NYSE: WAT) today announced first quarter 2018 sales of $531 million, a 7% increase
Read more →WATBryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full Year 2017 Financial Results Company Delivers Strong Fo
Contact: Bryan Brokmeier, CFA, Senior Director, Investor Relations, 508-482-3448 Corporation (NYSE: WAT) Reports Fourth Quarter and Full Year 2017 Financial Results Company Delivers Strong Fourth Quarter Revenue Growth from Key End Markets January 23, 2018 - Waters Corporati
Read more →WATJohn Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Corporation (NYSE: WAT) Reports Third Quarter 2017 Financial Results Company Delivers Strong Quarterly Reve
Contact: John Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Corporation (NYSE: WAT) Reports Third Quarter 2017 Financial Results Company Delivers Strong Quarterly Revenue Growth and Profitability Milford, Mass., October 24, 2017 - Waters Corpora
Read more →WATDoug Berthiaume to retire as Chairman of the Board of Waters Corporation; Chris O Connell Elected as New Chairman
Doug Berthiaume to retire as Chairman of the Board of Waters O Connell Elected as New Chairman MILFORD, Mass., October 19, 2017 Waters Corporation (NYSE: WAT) announced today that Douglas A. Berthiaume will retire as Chairman of the Board of Directors of the Company, effective
Read more →WATJohn Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Corporation (NYSE: WAT) Reports Second Quarter 2017 Financial Results Company Delivers Another Solid Quarte
Contact: John Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Corporation (NYSE: WAT) Reports Second Quarter 2017 Financial Results Company Delivers Another Solid Quarter of Revenue Growth and Profitability Milford, Mass., July 25, 2017 - Waters C
Read more →WATJohn Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Corporation (NYSE: WAT) Reports First Quarter 2017 Financial Results Company Delivers Revenue of $498 Milli
Waters Corporation (NYSE: WAT) Reports First Quarter 2017 Financial Results Company Delivers Revenue of $498 Million with Strong Growth in Core End Markets Milford, Mass., April 25, 2017 - Waters Corporation (NYSE: WAT) reported first quarter 2017 sales of $498 million, a 5% i
Read more →WATJohn Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Reports Fourth Quarter and Full Year 2016 Financial Results Company Delivers Fourth Quarter Revenue of $629
Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Reports Fourth Quarter and Full Year 2016 Financial Results Company Delivers Fourth Quarter Revenue of $629 Million and Diluted GAAP EPS of $2.15 (Non-GAAP EPS of $2.21) Milford, Mass., January 24, 2
Read more →WATJohn E. Lynch, Vice President of Investor Relations, 508-482-2314 Waters Corporation Announces Sherry Buck as Chief Financial Officer
Contact: John E. Lynch, Vice President of Investor Relations, 508-482-2314 Waters Corporation Announces Sherry Buck as Chief Financial Officer Dec. 8, 2016 Waters Corporation (NYSE:WAT) today announced Sherry Buck as its Senior Vice President and Chief Financial Officer effec
Read more →WATJohn Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Reports Third Quarter 2016 Financial Results Company Delivers Revenue of $527 Million and Diluted GAAP EPS
Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Reports Third Quarter 2016 Financial Results Company Delivers Revenue of $527 Million and Diluted GAAP EPS of $1.53 (Non-GAAP EPS of $1.57) Milford, Massachusetts, October 25, 2016 - Waters Corporat
Read more →WATJohn Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Reports Second Quarter 2016 Financial Results Company Delivers Revenue of $537 Million and Diluted GAAP EPS
Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Reports Second Quarter 2016 Financial Results Company Delivers Revenue of $537 Million and Diluted GAAP EPS of $1.57 (Non-GAAP EPS of $1.58) Milford, Massachusetts, July 26, 2016 - Waters Corporatio
Read more →WATJohn Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Reports First Quarter 2016 Financial Results Company Delivers Revenue of $475 Million and Non-GAAP EPS of $
Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Reports First Quarter 2016 Financial Results Company Delivers Revenue of $475 Million and Non-GAAP EPS of $1.26 Milford, Massachusetts, April 26, 2016 - Waters Corporation (NYSE: WAT) reported first
Read more →WATJohn Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Reports Fourth Quarter and Full Year 2015 Financial Results Strong Fourth Quarter Caps Milestone Year Milfo
Contact: John Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Reports Fourth Quarter and Full Year 2015 Financial Results Strong Fourth Quarter Caps Milestone Year Milford, Massachusetts, January 26, 2016 - Waters Corporation (NYSE: WAT) reported
Read more →WATWaters Corporation Expands Executive Team Waters Division President to Retire Key Leaders Elevated, Focused on Key Products and Markets
Waters Corporation Expands Executive Team Waters Division President to Retire Key Leaders Elevated, Focused on Key Products and Markets MILFORD, Mass. January 25, 2016 Waters Corporation (NYSE:WAT) today announced it will evolve and expand its leadership structure. The newly
Read more →WATJohn Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Reports Third Quarter 2015 Financial Results Broad-Based Growth Momentum Continues Milford, Massachusetts
Contact: John Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Reports Third Quarter 2015 Financial Results Broad-Based Growth Momentum Continues Milford, Massachusetts, October 27, 2015 - Waters Corporation (NYSE: WAT) reported today third quarter
Read more →WATJohn Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Reports Second Quarter 2015 Financial Results Milford, Massachusetts
Contact: John Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Reports Second Quarter 2015 Financial Results Milford, Massachusetts, July 28, 2015 - Waters Corporation (NYSE/WAT) reported today second quarter 2015 sales of $495 million, an increase
Read more →WATWaters Corporation Announces Christopher J. O Connell as Chief Executive Officer Milford, Mass.
Waters Corporation Announces Christopher J. O Connell as Chief Executive Officer Mass. - June 25, 2015 Waters Corporation (NYSE:WAT) today announced that Christopher J. O Connell has been appointed as its new President, Chief Executive Officer (CEO) and member of its Board of D
Read more →WATJohn Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Reports First Quarter 2015 Financial Results Milford, Massachusetts
Contact: John Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Reports First Quarter 2015 Financial Results Milford, Massachusetts, April 28, 2015 - Waters Corporation (NYSE/WAT) reported today first quarter 2015 sales of $460 million, an increase o
Read more →WATJoint Open Laboratory Established In China by Waters & the Chinese Pharmacopeia Commission Waters® Corporation (NYSE: WAT) recently announced the inauguration of its Joint Open Laboratory established together with the Chinese Pharmacopeia...
BEIJING , Jan. 28, 2015 /PRNewswire/ -- Waters ® Corporation (NYSE: WAT ) recently announced the inauguration of its Joint Open Laboratory established together with the Chinese Pharmacopeia Commission (ChP) during an opening ceremony held in Beijing . The analytic laboratory wil
Read more →WATJohn Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Reports Fourth Quarter 2014 Financial Results Milford, Massachusetts
Contact: John Lynch, Vice President, Treasurer and Investor Relations, 508-482-2314 Waters Reports Fourth Quarter 2014 Financial Results Milford, Massachusetts, January 26, 2015 Waters Corporation (NYSE/WAT) reported fourth quarter 2014 sales of $584 million, an increase of 3%
Read more →WATWaters Progenesis QI Marks Next Generation of LC-MS 'Omics Analysis at Analytica Waters Corporation (NYSE: WAT) today unveiled two new data analysis software packages for proteomics and metabolomics/lipidomics analyses:...
MUNICH , April 2, 2014 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today unveiled two new data analysis software packages for proteomics and metabolomics/lipidomics analyses: Progenesis ® QI and Progenesis QI for Proteomics. These new releases of the highly acclaimed software
Read more →WATWaters ACQUITY QDa Detector Takes Pittcon Editors' Award Waters Corporation (NYSE: WAT) is proud to announce that the Pittcon Editors' Silver award for the most innovative product introduced at the 2014...
CHICAGO , March 6, 2014 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) is proud to announce that the Pittcon Editors' Silver award for the most innovative product introduced at the 2014 Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy goes to the Waters ® A
Read more →WATWaters Marks Ten Years of ACQUITY UPLC; Looks to Future with ACQUITY QDa and ionKey/MS at Pittcon Waters® Corporation (NYSE: WAT) today celebrated the ten-year anniversary of the ACQUITY® UltraPerformance LC® (UPLC®) System, a technology that...
CHICAGO , March 3, 2014 /PRNewswire/ -- Waters ® Corporation (NYSE: WAT ) today celebrated the ten-year anniversary of the ACQUITY ® UltraPerformance LC ® (UPLC ® ) System , a technology that created a new industry standard for chromatographic performance. Looking forward, Waters
Read more →WATWaters Expands UNIFI Solutions with Three New Applications: Glycans, Forensic Toxicology and Natural Products Waters Corporation (NYSE: WAT) today announced three new UNIFI® Scientific Information System solutions: the Waters® Glycan Application Solution with ...
MILFORD, Mass. , Jan. 29, 2014 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today announced three new UNIFI ® Scientific Information System solutions: the Waters ® Glycan Application Solution with UNIFI, Forensic Toxicology Screening Application Solution with UNIFI, and the Na
Read more →WATWaters Introduces UPLC System for nano- to Microscale Separations - the ACQUITY UPLC M-Class System Waters Corporation (WAT:NYSE) today introduced the new Waters® ACQUITY UPLC® M-Class System, an industry-first nano- to microscale UltraPerformance...
MILFORD, Mass. , Jan. 28, 2014 /PRNewswire/ -- Waters Corporation (WAT:NYSE) today introduced the new Waters ® ACQUITY UPLC ® M-Class System , an industry-first nano- to microscale UltraPerformance LC ® (UPLC ® ) system rated for 15,000 psi operation. Coupled to Waters mass spect
Read more →WATThe Waters ACQUITY QDa Detector Named a Top Innovation for 2013 Waters Corporation (WAT:NYSE) announced today that its ACQUITY® QDa™ Detector was ranked among the top innovations of 2013 by The Analytical...
MILFORD, Mass. , Dec. 18, 2013 /PRNewswire/ -- Waters Corporation (WAT:NYSE) announced today that its ACQUITY ® QDa ™ Detector was ranked among the top innovations of 2013 by The Analytical Scientist magazine . (Logo: http://photos.prnewswire.com/prnh/20110707/NE31586LOGO ) Int
Read more →WATWaters Teams With Biochemical Society on Proteomics Training Day and Symposium Waters Corporation (NYSE: WAT) and the Biochemical Society announced today the opening of registration for the Biochemical Society's Quantitative...
MILFORD, Mass. , Nov. 27, 2013 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) and the Biochemical Society announced today the opening of registration for the Biochemical Society's Quantitative Proteomics Training Day and the ProteoMMX 3.0 Symposium , consecutive events taking pl
Read more →WATWaters Honors School of Pharmacy at University of Maryland Discovery and education were the main themes at a recent ceremony and symposium at the University of Maryland School of Pharmacy (UMSOP), an...
MILFORD, Mass. , Nov. 12, 2013 /PRNewswire/ -- Discovery and education were the main themes at a recent ceremony and symposium at the University of Maryland School of Pharmacy (UMSOP), an institution which Waters Corporation honored for its interdisciplinary research using mass s
Read more →WATWaters Introduces the ACQUITY QDa Detector, Bringing Push-Button Mass Detection to Chromatography Waters Corporation (NYSE: WAT) today introduced the new Waters® ACQUITY QDa™ Detector, the first mass detector to bring high-quality, mass spectral...
MILFORD, Mass. , Oct. 7, 2013 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today introduced the new Waters ® ACQUITY QDa™ Detector , the first mass detector to bring high-quality, mass spectral data to chromatographic separations. Waters is now shipping the new mass detector w
Read more →WATR&D 100 Award Goes to Waters ACQUITY UPC2 System Waters Corporation (NYSE: WAT) today announced that R&D Magazine recognized the Waters® ACQUITY UPC2™ System as one of the 100 most technologically...
MILFORD, Mass. , July 29, 2013 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today announced that R&D Magazine recognized the Waters ® ACQUITY UPC 2™ System as one of "the 100 most technologically significant products introduced into the marketplace over the past year." (Logo:
Read more →WATWaters Introduces CORTECS Columns Featuring Solid-Core Particle Technology Waters Corporation (NYSE: WAT) today introduced CORTECS™ Columns, a new family of 1.6 micron solid-core UltraPerformance LC® Columns that set a new...
AMSTERDAM , June 17, 2013 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today introduced CORTECS™ Columns , a new family of 1.6 micron solid-core UltraPerformance LC ® Columns that set a new standard in LC column performance. The higher efficiency brought to chromatography with
Read more →WATWaters Introduces the SYNAPT G2-Si to Its Mass Spectrometer Product Line Waters Corporation (NYSE:WAT) today unveiled the new Waters® SYNAPT® G2-Si Mass Spectrometer at the 61st conference of the American Society of Mass...
MINNEAPOLIS , June 10, 2013 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today unveiled the new Waters ® SYNAPT ® G2-S i Mass Spectrometer at the 61 st conference of the American Society of Mass Spectrometry (ASMS). The company is also previewing its UNIFI® CCS Research Editio
Read more →WATWaters Honors Flavor Research and Education Center at University of Minnesota At a ceremony at the University of Minnesota, Waters welcomed the Flavor Research and Education Center within the Food Science and Nutrition...
SAINT PAUL, Minn. , June 7, 2013 /PRNewswire/ -- At a ceremony at the University of Minnesota , Waters welcomed the Flavor Research and Education Center within the Food Science and Nutrition Department at the University of Minnesota into its Centers of Innovation Program . (Logo
Read more →WATSt. John's Research Institute Honored by Waters Center of Innovation Program At a ceremony at St. John's Research Institute (Bangalore, India) Waters announced the selection of the St. John's Research Institute for its Centers ...
MILFORD, Mass. , April 9, 2013 /PRNewswire/ -- At a ceremony at St. John's Research Institute ( Bangalore, India ) Waters announced the selection of the St. John's Research Institute for its Centers of Innovation Program for research in the field of structural proteomics. It is t
Read more →WATVICAM's New Immunoassay Column Detects Seven Mycotoxins in Single Run Waters Corporation (NYSE: WAT) today announced that VICAM®, a Waters® Business, introduced the Myco6in1+™ LC/MS/MS immunoaffinity (IA) column, the...
MILFORD, Mass. , April 2, 2013 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today announced that VICAM ® , a Waters ® Business, introduced the Myco6in1+™ LC/MS/MS immunoaffinity (IA) column, the only IA column on the market to simultaneously screen for seven major mycotoxin fa
Read more →WATWaters and Dow Announce Major Breakthrough in Advanced Polymer Analysis at Pittcon Waters Corporation (NYSE:WAT) today unveiled several important new technologies at the Pittsburgh Conference on Analytical Chemistry and Applied...
PHILADELPHIA , March 18, 2013 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today unveiled several important new technologies at the Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, commonly known as Pittcon, the annual premier conference and exposition o
Read more →WATWaters and DANI Instruments Announce Integrated and Compatible Network Waters Corporation (NYSE: WAT) and DANI Instruments today announced that Waters® Empower® Chromatography Data Software now provides control for DANI...
MILFORD, Mass. , March 14, 2013 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) and DANI Instruments today announced that Waters ® Empower ® Chromatography Data Software now provides control for DANI Headspace and Gas Chromatography instruments. Through this partnership, customer
Read more →WATWaters Updates Alliance HPLC Designs without Impacting Established Validated Methods Waters Corporation today reinforced its commitment to high performance liquid chromatography (HPLC) users through new design improvements to the...
MILFORD, Mass. , Feb. 25, 2013 /PRNewswire/ -- Waters Corporation today reinforced its commitment to high performance liquid chromatography (HPLC) users through new design improvements to the Waters ® Alliance ® HPLC System. Per customer demand, the updated system will maintain k
Read more →WATWaters Unveils Industry's First Integrated LC/MS Platform for Proteins, Peptides, and Glycans Analysis at WCBP 2013 Waters Corporation (NYSE: WAT) today reinforced its commitment to advancing biotherapeutic characterization technology at the Well Characterized...
WASHINGTON , Jan. 28, 2013 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today reinforced its commitment to advancing biotherapeutic characterization technology at the Well Characterized Biotechnology Pharmaceuticals 2013 Symposium (WCBP 2013) . More specifically, Waters ® toda
Read more →WATFera and Waters Open International Food Safety Training Laboratory A major new international food safety training facility, aimed at improving compliance with EU food import standards, is being launched today by The...
YORK, England , Jan. 22, 2013 /PRNewswire/ -- A major new international food safety training facility, aimed at improving compliance with EU food import standards, is being launched today by The Food and Environment Research Agency (Fera) and analytical equipment manufacturer Wat
Read more →WATBiological Mass Spectrometry Research Laboratory at Indiana University Receives Waters Center of Innovation Honors At a ceremony at Indiana University's Bloomington campus, Waters Corporation (NYSE: WAT) welcomed the Laboratory of Biological Mass Spectrometry and...
MILFORD, Mass. , Dec. 13, 2012 /PRNewswire/ -- At a ceremony at Indiana University's Bloomington campus, Waters Corporation (NYSE: WAT ) welcomed the Laboratory of Biological Mass Spectrometry and Professor David Clemmer , the Robert and Marjorie Mann Chair of Chemistry and the A
Read more →WATAutomated Online Sample Preparation Comes to Waters UltraPerformance Liquid Chromatography (UPLC) Platform Waters Corporation (NYSE:WAT) announced today that its ACQUITY UPLC® System is now available with online solid phase extraction (SPE) technology from ...
MILFORD, Mass. , Nov. 20, 2012 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) announced today that its ACQUITY UPLC ® System is now available with online solid phase extraction (SPE) technology from Spark Holland BV (Emmen, The Netherlands ). The Waters ® ACQUITY UPLC Online SPE
Read more →WATWaters Selects MTM Research Center at Orebro University for Center of Innovation Honors At a ceremony at the School of Science and Technology at Orebro University (Orebro, Sweden) Waters announced the selection of the MTM Research Center ...
MILFORD, Mass. , Nov. 5, 2012 /PRNewswire/ -- At a ceremony at the School of Science and Technology at Orebro University (Orebro, Sweden ) Waters announced the selection of the MTM Research Center for its Centers of Innovation Program for research in the field of persistent organ
Read more →WATWaters Selects Metabolomics Laboratory at University of North Texas for Center of Innovation Program Honors At a ceremony officiated by University of North Texas (UNT) Provost Warren Burggren, Waters Corporation (NYSE: WAT) welcomed UNT's Metabolomics and...
MILFORD, Mass. , Sept. 25, 2012 /PRNewswire/ -- At a ceremony officiated by University of North Texas (UNT) Provost Warren Burggren , Waters Corporation (NYSE: WAT ) welcomed UNT's Metabolomics and Metabolic Signaling Pathway Research Laboratory into the Waters Centers of Innovat
Read more →WATWaters and Nonlinear Dynamics to Co-Develop Next Generation Research Solutions for Large-Scale, Complex Data Sets Waters Corporation (WAT:NYSE) and Nonlinear Dynamics Ltd. have entered into an agreement to co-develop a new analytical solution that derives...
MILFORD, Mass. and NEWCASTLE UPON TYNE, England , Aug. 2, 2012 /PRNewswire/ -- Waters Corporation (WAT:NYSE) and Nonlinear Dynamics Ltd. have entered into an agreement to co-develop a new analytical solution that derives information from complex data sets generated by large-scale
Read more →WATVICAM's New DON-NIV WB Immunoaffinity Column Significantly Enhances Laboratory Analysis of Mycotoxins Waters Corporation (NYSE:WAT) today announced that VICAM®, a Waters® Business, introduced the DON-NIV™ WB Immunoaffinity (IA) column, the only IA...
MILFORD, Mass. , July 2, 2012 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today announced that V ICAM® , a Waters® Business, introduced the DON-NIV ™ WB Immunoaffinity (IA) column, the only IA column on the market to simultaneously screen for deoxynivalenol (DON) and nivaleno
Read more →WATWaters Breaks Ground on New Mass Spectrometry HQ in Wilmslow, UK Waters® Corporation (NYSE: WAT) held a groundbreaking ceremony for its new Mass Spectrometry Headquarters planned for completion in 2014. (Logo:...
MANCHESTER, England , June 18, 2012 /PRNewswire/ -- Waters ® Corporation (NYSE: WAT ) held a groundbreaking ceremony for its new Mass Spectrometry Headquarters planned for completion in 2014. (Logo: http://photos.prnewswire.com/prnh/20110707/NE31586LOGO ) The Right Honourable G
Read more →WATWaters Unveils New Analytical Tools for Research and Routine Screening Applications at ASMS 2012 Waters Corporation (WAT:NYSE) today revealed new mass spectrometers, new LC/MS instruments for pesticide residue screening and metabolite...
VANCOUVER, British Columbia , May 21, 2012 /PRNewswire/ -- Waters Corporation (WAT:NYSE) today revealed new mass spectrometers, new LC/MS instruments for pesticide residue screening and metabolite identification applications, and a new Omics Research Platform at the ASMS Conferen
Read more →WATWaters Brings Awarding-Winning UltraPerformance Convergence Chromatography to Analytica 2012 Waters Corporation (NYSE: WAT) is exhibiting its award-winning ACQUITY UPC(2)™ System for the first time in Europe at the 23rd Analytica...
MUNICH , April 17, 2012 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) is exhibiting its award-winning ACQUITY UPC(2) ™ System for the first time in Europe at the 23rd Analytica International Trade Fair for Laboratory Technology. A Gold Sponsor of this year's Analytica, Waters®
Read more →WATVICAM's New Fumo-V Strip Tests Delivers Accurate Detection of Fumonisin Mycotoxins in Minutes The Waters Corporation (NYSE:WAT) today announced VICAM®, a Waters® Business, introduced the Fumo-V™ strip test, the newest member of its...
MILFORD, Mass. , March 30, 2012 /PRNewswire/ -- The Waters Corporation (NYSE: WAT ) today announced VICAM® , a Waters ® Business, introduced the Fumo-V™ strip test , the newest member of its quantitative strip test family. Designed to work with the portable Vertu™ Lateral Flow Re
Read more →WATWaters, Ireland's NIBRT Partner on Training and Research to Advance Burgeoning Biopharma Industry The Irish National Institute for Bioprocessing Research and Training (NIBRT) and Waters® Corporation (NYSE: WAT) announced today they have formed a...
DUBLIN , March 27, 2012 /PRNewswire/ -- The Irish National Institute for Bioprocessing Research and Training (NIBRT) and Waters® Corporation (NYSE: WAT ) announced today they have formed a multi-level partnership designed to support advanced concepts and deliver the promise of mo
Read more →WATWaters ACQUITY UltraPerformance Convergence Chromatography Takes Pittcon Editors' Gold Award Waters Corporation (WAT: NYSE) was today awarded the prestigious 2012 Pittcon Editors' Gold Award for the new Waters® ACQUITY UPC(2)™ System as the...
ORLANDO, Fla. , March 15, 2012 /PRNewswire/ -- Waters Corporation (WAT: NYSE) was today awarded the prestigious 2012 Pittcon Editors' Gold Award for the new Waters® ACQUITY UPC(2)™ System as the best new product at the 2012 Pittsburgh Conference on Analytical Chemistry and Applie
Read more →WATWaters UltraPerformance Convergence Chromatography Ushers in New Category of Separation Science at Pittcon Waters Corporation (NYSE: WAT) today drew back the curtain on several important new technologies and a new business venture at Pittcon 2012, the...
ORLANDO, Fla. , March 12, 2012 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today drew back the curtain on several important new technologies and a new business venture at Pittcon 2012 , the industry's most important annual new product conference and exhibition. (Logo: http:/
Read more →WATThomson Mass Spectrometry Laboratory at Brazil's University of Campinas Selected as Waters Center of Innovation Waters Corporation (NYSE:WAT) today recognized the Thomson Mass Spectrometry Laboratory at the Institute of Chemistry at the University of Campinas...
MILFORD, Mass. , Jan. 30, 2012 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today recognized the Thomson Mass Spectrometry Laboratory at the Institute of Chemistry at the University of Campinas (UNICAMP), Campinas, Brazil as a Waters Center of Innovation . The Thomson Laborato
Read more →WATWaters ACQUITY UPLC and Xevo TQ-S Capable of Rapid Fungicide Detection in Orange Juice Using a Simple 'Dilute-and-Shoot' Procedure Waters Corporation (NYSE: WAT) today confirmed an analytical technique to rapidly determine residue levels of the fungicide carbendazim in orange...
MILFORD, Mass. , Jan. 23, 2012 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today confirmed an analytical technique to rapidly determine residue levels of the fungicide carbendazim in orange juice, with no sample preparation, at regulated levels by taking advantage of the ultr
Read more →WATWaters and NIBRT Complete Work on World's First UPLC Glycan Database Waters Corporation (WAT:NYSE) and Ireland's National Institute for Bioprocessing Research and Training (NIBRT) announced today the availability of...
MILFORD, Mass. , Jan. 20, 2012 /PRNewswire/ -- Waters Corporation (WAT:NYSE) and Ireland's National Institute for Bioprocessing Research and Training (NIBRT) announced today the availability of the world's first database for glycan analysis by UltraPerformance Liquid Chromatograp
Read more →WATWaters and Tecan Sign Agreement for Clinical Assay Platform To address the growing need for greater efficiencies and throughput that can be obtained with the automation of routine clinical laboratory assays,...
SAN DIEGO , Jan. 17, 2012 /PRNewswire/ -- To address the growing need for greater efficiencies and throughput that can be obtained with the automation of routine clinical laboratory assays, Waters Corporation (NYSE: WAT ) and Tecan Group (SIX Swiss Exchange: TECN) today entered i
Read more →WATWaters Gifts Research Equipment to University at Buffalo to Combat HIV/AIDS At a ceremony coinciding with the 20th anniversary of Los Angeles Laker Marvin Magic Johnson's public revelation that he had acquired HIV, the...
MILFORD, Mass. , Dec. 21, 2011 /PRNewswire/ -- At a ceremony coinciding with the 20th anniversary of Los Angeles Laker Marvin "Magic" Johnson's public revelation that he had acquired HIV, the University at Buffalo's School of Pharmacy and Pharmaceutical Sciences acknowledged Wate
Read more →WATFuture Fuels Institute at Florida State University Recognized as a Waters Center of Innovation Waters Corporation (NYSE: WAT) today welcomed the Future Fuels Institute at Florida State University, Tallahassee, Florida into its Centers of...
MILFORD, Mass. , Nov. 15, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today welcomed the Future Fuels Institute at Florida State University , Tallahassee, Florida into its Centers of Innovation Program . The Future Fuels Institute under its director, Dr. Chang S. (Sam) H
Read more →WATWaters, Mars and USAID Pledge $1 Million to Create Global Food Safety Capacity Building Fund Announced at the Asia-Pacific Economic Cooperation (APEC) meetings in Hawaii, Waters Corporation (NYSE: WAT), along with Mars Incorporated and the...
MILFORD, Mass. , Nov. 14, 2011 /PRNewswire/ -- Announced at the Asia-Pacific Economic Cooperation (APEC) meetings in Hawaii , Waters Corporation (NYSE: WAT ), along with Mars Incorporated and the U.S. Agency for International Development (USAID), jointly pledged $1 million to cre
Read more →WATWaters Recognizes the Dr. Ganesh Anand Laboratory at the National University of Singapore as Center of Innovation Waters Corporation (NYSE: WAT) today welcomed Dr. Ganesh Anand's laboratory at the National University of Singapore (NUS) into its Centers of...
MILFORD, Mass. and SINGAPORE , Oct. 24, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today welcomed Dr. Ganesh Anand's laboratory at the National University of Singapore (NUS) into its Centers of Innovation Program , making it the first such Center in Asia . With this des
Read more →WATWaters Empowers Advantar Laboratories for Sustained Growth Waters Corporation (NYSE: WAT) announced today that its customer Advantar Laboratories, Inc. (San Diego, CA) has successfully completed its rollout...
MILFORD, Mass. , Oct. 5, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) announced today that its customer Advantar Laboratories , Inc. ( San Diego, CA ) has successfully completed its rollout of Waters® Empower™ 3 Chromatography Software . The 21CFR Part 11 compliant-ready
Read more →WATWaters Honors University of Minnesota's Joseph Dalluge, Ph.D. and Department of Chemistry Mass Spectrometry Laboratory with Center of Innovation Recognition Waters Corporation (NYSE: WAT) today welcomed the University of Minnesota's Mass Spectrometry Laboratory into its Centers of Innovation Program....
MILFORD, Mass. , Oct. 3, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today welcomed the University of Minnesota's Mass Spectrometry Laboratory into its Centers of Innovation Program . Waters honored the Mass Spectrometry Laboratory under the direction of Joseph Dalluge ,
Read more →WATWaters Introduces New TruView LCMS Certified Vials for the Analytical Laboratory Waters Corporation (NYSE: WAT) today introduced TruView™ LCMS Certified Vials, a new line of low-adsorption sample vials certified for LC/MS/MS...
MILFORD, Mass. , Sept. 29, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today introduced TruView™ LCMS Certified Vials , a new line of low-adsorption sample vials certified for LC/MS/MS analyses where analyte concentrations are on the order of ng/mL or pg/mL and where ana
Read more →WATWaters, FDA and University of Maryland Open World's First International Food Safety Training Laboratory The U.S. Food and Drug Administration, University of Maryland, their Joint Institute for Food Safety and Applied Nutrition and Waters Corporation...
COLLEGE PARK, Md. , Sept. 15, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration, University of Maryland , their Joint Institute for Food Safety and Applied Nutrition and Waters Corporation (NYSE: WAT ) today opened the International Food Safety Training Laboratory, a gro
Read more →WATWaters Introduces the SQ Detector 2: Designed for the Routine, Prepared for the Unexpected Waters Corporation (NYSE: WAT) today introduced the Waters® SQ Detector 2, a new single quadrupole mass detector, at the 2011 JAIMA Expo (Japan...
MILFORD, Mass. , Sept. 6, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today introduced the Waters® SQ Detector 2 , a new single quadrupole mass detector, at the 2011 JAIMA Expo (Japan Analytical Instruments Manufacturers Association). Building on Waters' long standing ex
Read more →WATCenter for Proteomics at the Translational Genomics Research Institute (TGen) Selected as Waters Center of Innovation Waters Corporation (NYSE: WAT) today recognized the Center for Proteomics at the Translational Genomics Research Institute (TGen) as a Waters Center...
MILFORD, Mass. , Aug. 26, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today recognized the Center for Proteomics at the Translational Genomics Research Institute (TGen) as a Waters Center of Innovation . (Logo: http://photos.prnewswire.com/prnh/20110707/NE31586LOGO ) I
Read more →WATWaters CE Marks In Vitro Diagnostic MassTrak Immunosuppressants XE Kit Waters Corporation (NYSE: WAT) today announced that its MassTrak™ Immunosuppressants XE Kit is now CE-marked in accordance with the IVD Directive...
ATLANTA , July 25, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today announced that its MassTrak™ Immunosuppressants XE Kit is now CE-marked in accordance with the IVD Directive 98/79/EC, for the quantitative measurement of the immunosuppressive drugs tacrolimus (FK506;P
Read more →WATWaters Showcases ACQUITY UltraPerformance LC and Mass Spectrometry (UPLC/MS) Tools for Increasing Laboratory Efficiency at the American Association for Clinical Chemistry Annual Meeting Waters Corporation (NYSE: WAT) today unveiled new technology solutions for increasing clinical laboratory efficiencies including the first CE Marked...
ATLANTA , July 25, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today unveiled new technology solutions for increasing clinical laboratory efficiencies including the first CE Marked LC/MS/MS integrated solution for the quantification of everolimus (Certican®). (Logo: htt
Read more →WATWaters Recognizes Albert J. Fornace Laboratory at Georgetown University Medical Center as a Center of Innovation Waters Corporation (NYSE: WAT) today welcomed the metabolomics program at Georgetown University Medical Center (GUMC) into its Centers of Innovation...
MILFORD, Mass. , July 7, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today welcomed the metabolomics program at Georgetown University Medical Center (GUMC) into its Centers of Innovation Program and recognized Albert J. Fornace Jr. , MD, and Amrita Cheema, PhD, the direc
Read more →WATVICAM Introduces Vertu Lateral Flow Reader for Onsite and Laboratory Mycotoxin Detection The Waters Corporation (NYSE: WAT) today announced VICAM®, a Waters® Business, launched Vertu™, a digital lateral flow reader for fast, easy,...
MILFORD, Mass. , July 7, 2011 /PRNewswire/ -- The Waters Corporation (NYSE: WAT ) today announced VICAM®, a Waters® Business, launched Vertu™, a digital lateral flow reader for fast, easy, mycotoxin quantitation. The Vertu reader provides more accessible mycotoxin testing to food
Read more →WATWaters Unveils iPad Application at HPLC Conference to Aid Customer Selection of Key Consumables Waters Corporation (NYSE: WAT) today unveiled a suite of capabilities within one Apple iPad application that ensures customers can quickly and easily ...
MILFORD, Mass. , June 22, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today unveiled a suite of capabilities within one Apple iPad application that ensures customers can quickly and easily choose the most appropriate Waters ® ACQUITY UPLC ® sample plates, vials and filte
Read more →WATBrandon Ruotolo of the University of Michigan Receives ASMS Research Award At a ceremony held today during the 59th annual meeting of the American Society for Mass Spectrometry (ASMS), University of Michigan Dept. of...
DENVER , June 8, 2011 /PRNewswire/ -- At a ceremony held today during the 59th annual meeting of the American Society for Mass Spectrometry (ASMS), University of Michigan Dept. of Chemistry Assistant Professor Brandon Ruotolo received an ASMS 2011 Research Award in recognition of
Read more →WATWaters Introduces SYNAPT G2-S Mass Spectrometer, Combining Revolutionary StepWave Ion Optics With Ion Mobility Technology Taking Performance to New Level Waters Corporation (NYSE: WAT) today introduced the SYNAPT® G2-S High Definition Mass Spectrometer, representing a significant step forward in...
DENVER , June 6, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today introduced the SYNAPT® G2-S High Definition Mass Spectrometer, representing a significant step forward in performance for High Definition Mass Spectrometry. The SYNAPT G2-S incorporates both high-sensitiv
Read more →WATWaters Corporation and PREMIER Biosoft International Announce Collaboration for Advancing Lipidomics Research Waters Corporation (NYSE: WAT) today announced it has entered into a non-exclusive co-marketing and reselling agreement with PREMIER Biosoft...
DENVER , June 6, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today announced it has entered into a non-exclusive co-marketing and reselling agreement with PREMIER Biosoft International ( Palo Alto, CA ) to advance lipidomics research. Waters will offer PREMIER Biosoft's
Read more →WATWaters Introduces the New Xevo TQD Mass Spectrometer, the Most Versatile Technology Platform in Its Class Waters Corporation (NYSE: WAT) today introduced its new Xevo® TQD tandem quadrupole mass detector, bringing the Waters® design philosophy of...
DENVER , June 6, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today introduced its new Xevo® TQD tandem quadrupole mass detector, bringing the Waters® design philosophy of Engineered Simplicity™ to routine quantitative LC/MS/MS analysis. The newest addition to the Waters
Read more →WATArista Laboratories Purchases Waters NuGenesis Scientific Data Management System (SDMS) to Bring Laboratories into Adherence With Good Laboratory Practices (GLP) Waters Corporation (NYSE: WAT) announced today that Arista Laboratories (Richmond, VA) has purchased the Waters NuGenesis® Scientific Data Management ...
MILFORD, Mass. , May 13, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) announced today that Arista Laboratories ( Richmond, VA ) has purchased the Waters NuGenesis® Scientific Data Management System (SDMS) software in order to become the first such laboratory to offer GLP
Read more →WATWaters Welcomes Duke University Proteomics Core Facility into Centers of Innovation Program Waters Corporation (NYSE: WAT) today welcomed into its Centers of Innovation Program the Proteomics Core Facility at the Duke University School of...
MILFORD, Mass. , May 11, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today welcomed into its Centers of Innovation Program the Proteomics Core Facility at the Duke University School of Medicine ( Durham, NC ). In a ceremony at Duke University , Waters recognized Associat
Read more →WATFrost & Sullivan: Waters Xevo MS Systems Offer Unequalled Combination of Separations Power and Sensitivity Waters Corporation (NYSE: WAT) today announced that it has been awarded the 2011 North American Product Quality Leadership Award in high-performance...
MILFORD, Mass. , March 14, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today announced that it has been awarded the 2011 North American Product Quality Leadership Award in high-performance mass spectrometry by Frost & Sullivan. Specifically, Frost & Sullivan researchers
Read more →WATWaters Expands Impact of UPLC Technology with New SFC, Process Development LC, and 2D LC Systems at Pittcon 2011 Waters Corporation (NYSE: WAT) today unveiled three new Waters® ACQUITY UPLC® Systems further extending the impact of sub-two micron separation...
ATLANTA , March 14, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today unveiled three new Waters® ACQUITY UPLC® Systems further extending the impact of sub-two micron separation technology to address targeted analytical challenges. The addition of the Waters ACQUITY Ultra
Read more →WATWaters Extends Early Registration Deadline for 6th International Symposium on Mass Spectrometry and Related Techniques in Advanced Analytical Science Waters Corporation (NYSE: WAT) has extended the early registration deadline to March 4 for the 6th International Symposium on MS and Related...
MILFORD, Mass. , Feb. 23, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) has extended the early registration deadline to March 4 for the 6th International Symposium on MS and Related Techniques in Advanced Analytical Science , taking place April 12 – 14 at the Hilton Manche
Read more →WATWaters Releases NuGenesis SDMS 7.1 Validated to Support Windows 7 and Empower 3 CDS Waters Corporation (NYSE: WAT) today announced the release of NuGenesis® Scientific Data Management System 7.1 Service Release 7 (SR-7), structurally ...
MILFORD, Mass. , Jan. 27, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today announced the release of NuGenesis® Scientific Data Management System 7.1 Service Release 7 (SR-7), structurally validated to support Microsoft's Windows 7, both Professional and Enterprise 32bit
Read more →WATWaters to Build New Mass Spectrometry Headquarters Near Manchester, U.K. Waters Corporation (NYSE: WAT) today announced it signed a land-purchase agreement with The Royal Bank of Scotland for a new Mass Spectrometry (MS)...
MANCHESTER, England , Jan. 20, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today announced it signed a land-purchase agreement with The Royal Bank of Scotland for a new Mass Spectrometry (MS) Headquarters in Wilmslow, Cheshire, near Manchester, U.K. Situated on the 37-a
Read more →WATWaters Combines Best-in-Class Performance, Versatility and Usability Technologies in New Xevo G2 Tof Benchtop System Waters Corporation (NYSE: WAT) today introduced the Waters® Xevo® G2 Tof (time-of-flight) mass spectrometer (MS) with UPLC®/MS(E) and QuanTof™...
MILFORD, Mass. , Jan. 10, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today introduced the Waters® Xevo® G2 Tof (time-of-flight) mass spectrometer (MS) with UPLC®/MS(E) and QuanTof™ technology, which offers the most sensitive, exact mass quantitative and qualitative perf
Read more →WATWaters New Biopharmaceutical System Solution Uniquely Unites UPLC/MS Analyses and Workflows Driven by Industry First Scientific Information System Waters Corporation (NYSE: WAT) today introduced its Waters® Biopharmaceutical System Solution at WCBP, the 15th Symposium on the Interface of...
MILFORD, Mass. , Jan. 10, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today introduced its Waters® Biopharmaceutical System Solution at WCBP, the 15th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products in Washington, D.C. T
Read more →WATWaters Empower 3 Answers Call for a Standardized Chromatography Data System at Enterprise-Level Waters Corporation (NYSE: WAT) today introduced Waters® Empower™ 3 Chromatography Data System (CDS), a scalable, enterprise-wide CDS platform that...
MILFORD, Mass. , Nov. 30, 2010 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today introduced Waters® Empower™ 3 Chromatography Data System (CDS), a scalable, enterprise-wide CDS platform that can be rapidly deployed to easily fit into existing corporate infrastructure. "One o
Read more →WATWaters Corporation Welcomes King's College London into Waters Centers of Innovation Program Waters Corporation (NYSE: WAT) today welcomed into its Centers of Innovation Program the Drug Control Centre within the Department of Forensic...
MILFORD, Mass. , Nov. 10, 2010 /PRNewswire-FirstCall/ -- Waters Corporation (NYSE: WAT ) today welcomed into its Centers of Innovation Program the Drug Control Centre within the Department of Forensic Science and Drug Monitoring at King's College London. In a symposium and cerem
Read more →WATSupporting Scientific Invention, Waters Corporation Launches Centers of Innovation Program Waters Corporation (NYSE: WAT) today launched a new program to support scientific innovation in the fields of health and life science research,...
MILFORD, Mass. , Nov. 2, 2010 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today launched a new program to support scientific innovation in the fields of health and life science research, sports science, food safety, clinical research and environmental protection. Through its
Read more →WATWaters and Hitachi High Technologies America Enter into Distribution Agreement for Chromatography and Mass Spectrometry Consumables Waters Corporation (NYSE: WAT) and Hitachi High Technologies America, Inc. ( HTA ) have entered into an agreement granting HTA the ability to sell...
MILFORD, Mass. , Sept. 16 /PRNewswire-FirstCall/ -- Waters Corporation (NYSE: WAT ) and Hitachi High Technologies America, Inc. ("HTA") have entered into an agreement granting HTA the ability to sell Waters® sample preparation and liquid chromatography (LC) columns to Hitachi use
Read more →WATWaters Introduces Ostro Sample Preparation Products Waters Corporation (NYSE: WAT) today introduced the new Ostro™ Sample Preparation Plate, representing a novel approach for the removal of...
MILFORD, Mass. , Sept. 14 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today introduced the new Ostro™ Sample Preparation Plate, representing a novel approach for the removal of phospholipids from biological samples. When compared to other phospholipid removal devices and trad
Read more →WATWaters Corporation and UCLA to Convene Leading Life Scientists Waters Corporation (NYSE: WAT) and the University of California at Los Angeles (UCLA) will bring together some of the world's leading life science...
MILFORD, Mass. , Sept. 3 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) and the University of California at Los Angeles ( UCLA ) will bring together some of the world's leading life science researchers and practitioners of mass spectrometry (MS) at a conference next month to dis
Read more →WATEPA Laboratory Publishes Direct Injection UPLC/MS/MS Methods for Chemical Dispersants in Sea Water The United States Environmental Protection Agency (EPA) has published two rapid screening methods for chemical dispersants in sea waters using...
MILFORD, Mass. , Sept. 2 /PRNewswire/ -- The United States Environmental Protection Agency (EPA) has published two rapid screening methods for chemical dispersants in sea waters using Waters® ACQUITY UPLC®/Quattro Premier™ XE (UPLC/MS/MS). These analytical procedures were develop
Read more →Competitive Position
How WAT ranks across every disease it competes inCompetitive Position is a premium feature
See how WAT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial